Document:

Document

Exhibit 10.1
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL

Execution Version

EXCLUSIVE LICENSE AGREEMENT

by and between

CARNA BIOSCIENCES, INC.

and

BRICKELL BIOTECH, INC.

EXCLUSIVE LICENSE AGREEMENT
This Exclusive License Agreement (this “Agreement”) is entered into as of February 2, 2022 (the “Effective Date”) by and between Carna Biosciences, Inc., a corporation organized under the laws of Japan (or, Nippon-koku) having a principal place of business at BMA 3F, 1-5-5, Minatojima-minamimachi, Chuo-ku, Kobe 650-0047, Japan (“Licensor”) and Brickell Biotech, Inc., a Delaware corporation having a principal place of business at 5777 Central Avenue, Suite 102, Boulder, Colorado, USA 80301 (“Licensee”). Licensor and Licensee are sometimes herein referred to individually as a “Party” and collectively as the “Parties”.
RECITALS
Whereas, Licensor owns the rights to the stimulator of interferon genes (“STING”) inhibitor known as [***] and other STING inhibitors, which Licensor is developing, in part, for [***];
Whereas, Licensee possesses resources and expertise in the global development, manufacture, marketing and commercialization of pharmaceutical products; and
Whereas, the Parties desire to enter into an exclusive worldwide license relating to [***] and other STING inhibitors, all as set forth herein. 
Now, Therefore, in consideration of the foregoing premises and the mutual promises, covenants and conditions contained in this Agreement, the Parties hereby agree as follows:
ARTICLE 1
DEFINITIONS
“Acquiror” has the meaning set forth in Section 15.5.
“Affiliate” means, with respect to either Party, any person, firm, trust, corporation, subsidiary, limited liability entity, partnership, or other entity or combination thereof that directly or indirectly controls, is controlled by, or is under common control with such Party; and for purposes of this definition, the term “control” (including, with correlative meaning, the terms “controlled by” or “under common control with”) means direct or indirect ownership of fifty percent (50%) or more of the voting and equity rights of such person, firm, trust, corporation, subsidiary, limited liability entity, partnership, or other entity or combination thereof, or the power to direct the management of such person, firm, trust, corporation, partnership, or other entity or combination thereof. This definition applies to entities created under any country’s laws.
“Agreement” has the meaning set forth in the Preamble. 
“Application for Drug Approval” means, with respect to a Product, (i) in the United States, an NDA, and (ii) in any country or regulatory jurisdiction other than the United States, an application or set of applications for Drug Approval comparable to an NDA.
“Bankruptcy Code” means, as applicable, the U.S. Bankruptcy Code, as amended from time to time, and the rules and regulations and guidelines promulgated thereunder or the bankruptcy laws of any Governmental Authority, as amended from time to time, and the rules and regulations and guidelines promulgated thereunder or any applicable bankruptcy laws of any other country or Governmental Authority, as amended from time to time, and the rules and regulations and guidelines promulgated thereunder.
    1

“Breaching Party” has the meaning set forth in Section 13.3(a).
“Business Day” means any day other than a day on which the commercial banks in New York, New York, USA are authorized or required to be closed.
“Calendar Quarter” means each successive period of three (3) calendar months commencing on January 1, April 1, July 1 and October 1, except that the first Calendar Quarter of the Term commences on the Effective Date and ends on the first to occur of March 31, June 30, September 30 and December 31 after the Effective Date, and the last Calendar Quarter ends on the last day of the Term.
“Calendar Year” means each successive period of twelve (12) calendar months commencing on January 1 and ending on December 31, except that the first Calendar Year of the Term commences on the Effective Date and ends on December 31 of the year in which the Effective Date occurs and the last Calendar Year of the Term commences on January 1 of the year in which the Term ends and ends on the last day of the Term.
“Change of Control” means, with respect to either Party, (a) the sale of all or substantially all of such Party’s assets or business relating to this Agreement; (b) a merger (including a reverse triangular merger), consolidation, share exchange or other similar transaction involving such Party and any Third Party which results in the holders of the outstanding voting securities of such Party, or any Affiliate that controls such Party directly or indirectly, immediately before such merger, consolidation, share exchange or other similar transaction ceasing to hold more than fifty percent (50%) of the combined voting power of the surviving, purchasing or continuing entity immediately after such merger, consolidation, share exchange or other similar transaction, or (c) the acquisition by a person or entity, or group of persons or entities acting in concert, of more than fifty percent (50%) of the outstanding voting equity securities of such Party; in all cases of clauses (a)–(c), where such transaction is to be entered into with any person or group of persons other than the other Party or its Affiliates.
“Claims” has the meaning set forth in Section 11.1.
“Clinical Study” means a research study using human subjects to evaluate biomedical or health-related outcomes, including a Phase 1 Study, a Phase 2 Study, a Phase 3 Study, a phase 4 study or post-approval study, an observational study, or variations of such studies (e.g., Phase 2/3).
“CMC Information” means Information related to the chemistry, manufacturing and controls of a product, as specified by the FDA, EMA, PFSB or PMDA and other applicable Regulatory Authorities.
“Combination Product” has the meaning set forth in the definition of Net Sales.
“Commercial Sublicense Agreement” means, with respect to any Product, an agreement pursuant to which Licensee grants to a Third Party a sublicense under the STING Inhibitor License that includes the right to Commercialize such Product in the Field in all or part of the Territory, but excluding any agreement that merely grants such Third Party the right to distribute such Product or to perform services with respect to such Product.
“Commercialization”, with a correlative meaning for “Commercialize” and “Commercializing”, means any and all activities undertaken before and after obtaining Regulatory Approvals relating specifically to the commercialization and pre-launch, launch, promotion, detailing, labeling, bidding and listing, marketing, pricing, reimbursement, formulary management, sale, selling, having sold, importing, having imported, exporting, having exported, 
2

distributing, having distributed, supply and distribution (including storage and handling) of Product, including strategic marketing, sales force detailing, advertising, and market and Product support, and all customer service and support, Product distribution, invoicing, conducting medical affairs, conducting post-marketing safety surveillance and reporting and sales activities and other similar activities. Commercialization does not mean activities that are non-promotional or not for the purpose of selling or priming the market for Product launch, or that are intended for scientific exchange.
“Commercially Reasonable Efforts” means, with respect to a Party’s obligations or tasks under this Agreement with respect to the performance of any activities by a Party hereunder, the level of efforts and resources that a Party would reasonably devote to the Development and Commercialization of a comparable product of similar market potential or profit potential for the affected country or region resulting from its own research and development efforts, taking into account efficacy, safety, tolerability, patent and regulatory exclusivity, anticipated or approved labeling or laws, present and future market potential, competitive market conditions (including Generic Product and competitive or comparable product market penetration), the profitability of a Product in light of pricing, access and reimbursement, and formulary management, and other considerations, including rebates or coupons under risk-sharing schemes, chargebacks, discounts of any type, loyalty programs, free samples, reference pricing, parallel pricing, cost of goods, supply chain dynamics, availability of partners and qualified personnel, and all other relevant scientific, technical, financial, marketing and commercial factors. Commercially Reasonable Efforts shall be determined on, and may differ by, a country-by-country basis and may include, but not be limited to, activities that support partnering or sublicensing arrangements, or the like, in certain countries where Licensee in its reasonable business judgment decides not to have a direct presence, or where applicable Law would not allow a direct presence or presence without a local partner. 
“Competitive Product” means any compound or product that [***]. Notwithstanding the foregoing, any compound or product [***] will be deemed a Competitive Product.
“Compound” means (a) the compound known as [***] that is an inhibitor of STING activity, the chemical structure of which is set forth in Exhibit B of this Agreement, (b) any other compound of which its composition of matter, use, or manufacture thereof is Covered by a Licensor Patent or disclosed or encompassed by one or more genera or subgenera disclosed in a Licensor Patent, in each case, existing as of the Effective Date or claiming priority to any Licensor Patent existing as of the Effective Date, and (c) any metabolite or stereoisomer thereof, and any salt form, crystal form, or prodrug of any of the foregoing compounds described in clauses (a) and (b).
“Confidential Information” of a Party means any and all Information that is disclosed by or on behalf of such Party or its Affiliates to the other Party or its Affiliates under this Agreement, or is otherwise obtained by the other Party or its Affiliates as part of the implementation of the Agreement, whether in oral, written, tangible, graphic, or electronic or other form(s), that can reasonably be expected by a Party to be treated as confidential and proprietary of the other Party or its Affiliates, or which is labeled or marked as confidential information of the Party.
“Control” (including any variations such as “Controlled” and “Controlling”) means, with respect to any material, Information, or intellectual property right, that a Party (a) owns or (b) has a license (other than a license granted to such Party under this Agreement), right or covenant to such material, Information, or intellectual property right, and in each case, has the ability to grant to the other Party access, a license, or a sublicense (as applicable) to the foregoing on the terms and conditions set forth in this Agreement without violating the terms of any then-existing agreement or other arrangement with any Third Party.
3

“Cover” means, with respect to a Patent, a Compound, and a Product, that the Exploitation of such Compound or Product by an unlicensed Third Party would infringe a Valid Claim in such Patent, or, with respect to a Patent application, a claim in such Patent application as if issued in the form then currently being prosecuted. “Covered” and “Covering” shall have the correlative meanings.
“Default Notice” has the meaning set forth in Section 13.3(a).
“Develop” or “Development” means any and all activities relating to preparing and conducting non-Clinical Studies, Clinical Studies, and regulatory activities (e.g., preparation of regulatory applications, responding to or interacting with regulators, etc.) that are necessary or useful to obtain and maintain Drug Approval of a Product (excluding regulatory and any other activities directed to obtaining pricing, access and reimbursement for the Product).
“Development/Regulatory Milestones” has the meaning set forth in Section 8.2(a).
“Dispute” has the meaning set forth in Section 14.1.
“Dollars” or “$” means U.S. dollars.
“Drug Approval” means an approval granted by the appropriate Regulatory Authority to market a Product in the Field in any particular jurisdiction in the Territory, excluding any required Pricing and Reimbursement Approval.
“Effective Date” has the meaning set forth in the Preamble.
“EMA” means the European Medicines Agency or any successor entity.
“EU” means the European Union member states, as constituted on the Effective Date and as it may be expanded or contracted from time to time following such date during the Term of this Agreement.
“Exploit” means, with respect to any compound or product, to research, make, have made, register, use, sell, offer for sale, import, export, and otherwise exploit such compound or product, including, with respect to Compound or Product, to Develop and Commercialize such Compound and Product. “Exploiting” or “Exploitation” shall have the correlative meanings. 
“FD&C Act” means the U.S. Federal Food, Drug, and Cosmetic Act, as amended.
“FDA” means the U.S. Food and Drug Administration or any successor entity.
“Field” means all uses (including any and all uses for the diagnosis, prevention, control, amelioration, and treatment of any disease, disorder or medical condition in animals or humans).
“First Commercial Sale” means, with respect to a Product in a given country or regulatory jurisdiction, the first sale for monetary value for use or consumption by the end user of such Product to a Third Party in a given country or regulatory jurisdiction after Drug Approval (and, to the extent required by applicable Law, the Pricing and Reimbursement Approval) has been obtained in such jurisdiction. Sales of any type or form [***], such as so-called [***] shall not be construed as a “First Commercial Sale”.
“GAAP” means U.S. generally accepted accounting principles, consistently applied.
4

“Generic Product” means, with respect to a Product (the “Reference Product”), any pharmaceutical product in a particular regulatory jurisdiction that (a) contains the same active pharmaceutical ingredient(s) as the Reference Product and has one or more Regulatory Authority-approved Indications in such jurisdiction equivalent to any of the Regulatory Authority-approved Indications for the Reference Product in such jurisdiction; and (b) is sold in such jurisdiction by a Third Party that is not a Sublicensee of Licensee or its Affiliates, and is not otherwise authorized by Licensee or any of its Affiliates, or Sublicensees to sell such product.
“GMP” means the then-current standards relating to Good Manufacturing Practices for fine chemicals, active pharmaceutical ingredients, intermediates, bulk products, and/or finished pharmaceutical products set forth in (i) 21 U.S.C. 351(a)(2)(B), in FDA regulations at 21 C.F.R. Parts 210 and 211, (ii) the Rules Governing Medicinal Products in the European Community, Volume IV, Good Manufacturing Practice for Medicinal Products, and/or (iii) the principles detailed in ICH Guidelines relating to the manufacture of active pharmaceutical ingredient and finished pharmaceuticals, and/or (iv) the equivalent applicable law in any relevant country, as such standards may be updated from time to time, including applicable quality guidelines promulgated under the ICH. 
“Good Laboratory Practice” or “GLP” means the then-current good laboratory practice standards promulgated or endorsed by the FDA as defined in 21 C.F.R. Part 58, and comparable regulatory standards promulgated by the EMA, PFSB or PMDA, or other Regulatory Authority applicable to the Territory in which a Product is intended to be Commercialized to the extent such standards are not less stringent than the FDA GLP, and as such standards may be updated from time to time, including applicable quality guidelines promulgated under the ICH.
“Governmental Authority” means any multi-national, federal, state, local, municipal, provincial, or other governmental authority of any nature (including any governmental division, prefecture, subdivision, department, agency, bureau, branch, office, commission, council, court, or other tribunal).
“HSR Act” means the U.S. Hart-Scott-Rodino Antitrust Improvements Act of 1976.
“ICH” means the International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use.
“ICH Guidelines” means the guidelines of the ICH. 
“IND” means an Investigational New Drug Application with the FDA, as defined in the FD&C Act, or any equivalent Regulatory Materials in a country other than the U.S.
“IND-Enabling Preclinical GLP Study” means, with respect to the Product, any preclinical genotoxicity, acute toxicology, safety, pharmacology, or sub-chronic toxicology study of the Product using applicable GLP that satisfies applicable regulatory requirements and meets the standard necessary for submission as part of an IND filing with a Regulatory Authority for the Product, including the IND-Enabling Preclinical GLP Toxicology Study.  
“IND-Enabling Preclinical GLP Toxicology Study” means, with respect to the Product, an in vivo preclinical research study that is designed to determine the toxicology effects of the Product that (a) satisfies applicable regulatory requirements using GLP, (b) is designed to meet the standard necessary for submission as part of an IND filing with a Regulatory Authority for the Product, and (c) is required to enable the commencement of dosing of the Product in a Clinical Study.
“Indemnified Party” has the meaning set forth in Section 11.3.
5

“Indemnifying Party” has the meaning set forth in Section 11.3.
“Indication” means any disease, disorder, or condition (i) for which a Product is indicated for treatment and (ii) that is described in the Product label as required by the Drug Approval granted by the applicable Regulatory Authority, for which a separate Registrational Study is required. For clarity, (i) uses of the Product for the same disease for different populations or population subtypes, or in an expanded, modified or additional patient population, including pediatric patients, are not different Indications; (ii) the approved use in different combinations or co-therapies of treatments are not different Indications (e.g., monotherapy vs. add-on or combination therapy with another agent in the same disease); and (iii) treatment and prevention of the same disease, or subtype are not different Indications.
“Information” means all data, results, technology, business or financial information or information of any type whatsoever, in any tangible or intangible form, including know-how, trade secrets, practices, techniques, methods, processes, inventions, discoveries, developments, specifications, formulations, formulae, materials, or compositions of matter of any type or kind (patentable or otherwise), software, algorithms, marketing or other reports, strategic, business and operational plans, expertise, technology, test data (including pharmacological, biological, chemical, biochemical, clinical test, or study data and data resulting from non-Clinical Studies), CMC Information, Regulatory Materials, stability data, manufacturing data and other study data and procedures.
“Inventions” means all ideas, discoveries, inventions, modifications, improvements, enhancements, or new uses, whether or not patentable, and whether or not reduced to practice, discovered, made, or conceived in the course of activities contemplated or required by this Agreement.
“JAMS Rules” has the meaning set forth in Section 14.1.
“Law” means all applicable laws, statutes, rules, regulations, ordinances, and other pronouncements having the effect of law of any federal, national, multinational, state, local, provincial, county, city, or other political subdivision, domestic or foreign.
“Licensee” has the meaning set forth in the Preamble. 
“Licensee Indemnitees” has the meaning set forth in Section 11.1.
“Licensee Know-How” means all Information that (a) is necessary or useful for the Development, manufacture, or Commercialization of any Compound or Product in the Field, (b) is Controlled by Licensee or its Affiliates during the Term and (c) actually used by Licensee, its Affiliates or sublicensees in the Development, manufacture or Commercialization of the Compound or Product in the Field; provided, the use of “Affiliate” in this definition excludes any Third Party that becomes an Affiliate of Licensee after the Effective Date due to a Change of Control of Licensee.
“Licensee Patent” means any Patent (other than a Licensor Patent) that (a) Covers, generically or specifically, any Compound or Product, or the manufacture or use in the Field of any Compound or Product, (b) which is Controlled by Licensee or its Affiliates during the Term, and (c) actually used by Licensee, its Affiliates or sublicensees in the Development, manufacture or Commercialization of the Compound or Product in the Field; provided, the use of “Affiliate” in this definition excludes any Third Party that becomes an Affiliate of Licensee after the Effective Date due to a Change of Control of Licensee.
“Licensee Technology” means the Licensee Know-How and Licensee Patents.
6

“Licensor” has the meaning set forth in the Preamble. 
“Licensor Indemnitees” has the meaning set forth in Section 11.2.
“Licensor Know-How” means all Information that (a) is necessary or useful for the Exploitation of any Compound or Product in the Field and (b) is Controlled by Licensor or its Affiliates as of the Effective Date or during the Term; provided, the use of “Affiliate” in this definition excludes [***].
“Licensor Patent” means any Patent (other than a Licensee Patent) that (a) Covers, generically or specifically, any Compound or Product, or the Exploitation in the Field of any Compound or Product and (b) (i) is Controlled by Licensor or its Affiliates as of the Effective Date, (ii) is Controlled by Licensor or its Affiliates during the Term and claims priority to a Patent Controlled by Licensor or its Affiliates as of the Effective Date, and/or (iii) is Controlled by Licensor or its Affiliates during the Term; in each case of (a) and (b), including such Patents set forth in Exhibit A hereto, which will be updated by the Parties from time to time during the Term; provided, that the use of “Affiliate” in this definition excludes [***].
“Licensor Technology” means the Licensor Know-How and the Licensor Patents.
“Major Market Countries” means the following countries: [***].
“Milestones” means collectively the Development/Regulatory Milestones and the Net Sales Milestones.
“NDA” means a New Drug Application filed with the FDA pursuant to 21 U.S.C. Section 357 and 21 C.F.R. Section 314 or any successor regulatory scheme.
“Net Sales” means, with respect to any Product, the gross sales amount actually received by Licensee or its Affiliates or Sublicensees (each, a “Selling Party”) to each Third Party receiving such Product in arm’s length transactions, less the following deductions (to the extent not already deducted before receipt of such gross sales amount) from such total amounts that are actually incurred, allowed, accrued or specifically allocated:
(a)    [***];
(b)    [***];
(c)    [***];
(d)    [***]; and 
(e)    [***];
provided that, in each case ((a) through (e)), (i) each such deduction is calculated in a manner consistent with the Selling Party’s customary practice for pharmaceutical products and in accordance with GAAP, consistently applied by the Selling Party, (ii) each such deduction is [***], or apportioned on a good faith, fair and equitable basis to [***] such that [***] of such deductions, and (iii) no particular amount identified above shall be deducted [***] in calculating Net Sales (i.e., no [***] deductions).
For avoidance of doubt, [***], in each case, shall not be included in Net Sales.
7

In the event that a Product is sold in a given country together with one or more other therapeutically active ingredients or therapies not constituting a Product for a single price (regardless of their packaging) (a “Combination Product”), such Product shall be deemed to be sold in such country for an amount equal to [***]. 
In the event of any sale or other disposition of Product for any consideration other than exclusively monetary consideration on bona fide arm’s-length terms, then for purposes of calculating Net Sales under this Agreement, such Product shall be deemed to have been sold [***]. 
For this definition:
(x)    the transfer of Product by a Selling Party to [***] is not considered a sale; 
(y)     the transfer of Product by a Selling Party to [***] is not considered a sale; and 
(z)    [***] is not a sale under this definition. 
For clarity, there is [***]. [***] are permitted within customary limits for the pharmaceutical industry. The amount of Product transferred pursuant to subsections (x), (y) and (z) of this definition is determined from the books and records of the Selling Party, maintained in accordance with GAAP.
“Net Sales Milestones” has the meaning set forth in Section 8.2(c). 
“Non-Breaching Party” has the meaning set forth in Section 13.3(a).
“Non-Governmental Authority” means any public or private body (including the National Institute of Clinical Excellence and the Scottish Medicines Consortium in the United Kingdom; the Institute for Quality and Efficiency in Healthcare in Germany; the Technical Scientific Commission in Italy; the Directorate of Pharmacy and Healthcare Products in Spain; the National Union of Health Insurance Funds and the National Authority of Health in France; and Health Canada in Canada) or non-Governmental Authority (including “Sick Funds” in Germany) with the authority to control, approve, recommend or otherwise determine pricing, access and reimbursement or the like related to pharmaceutical products, including those with authority to enter into risk-sharing schemes or to impose retroactive price reductions, discounts, rebates, chargebacks, or the like.
“Paragraph IV Notice” has the meaning set forth in Section 9.3(h).
“Party” or “Parties” has the meaning set forth in the Preamble. 
“Patents” means (a) pending patent applications, including all provisionals, non-provisionals, international patent applications filed under the Patent Cooperation Treaty (PCT) and any foreign equivalents to any of the foregoing, issued or allowed patents, utility models and designs anywhere in the world; (b) reissues, substitutions, confirmations, amendments, registrations, validations, re-examinations, additions, continuations, continued prosecution applications, continuations-in-part, or divisions of or to any of the foregoing; (c) any other patent or patent application claiming priority to any of the foregoing anywhere in the world; and (d) extension, renewal, or restoration of any of the foregoing by existing or future extension, renewal, or restoration mechanisms, including supplementary protection certificates or the equivalent thereof.
“Payee” has the meaning set forth in Section 8.6.
8

“PFSB” means the Pharmaceutical and Food Safety Bureau of the Japan Ministry of Health, Labor & Welfare (“MHLW”).
“Phase 1 Study” means a human clinical trial with the endpoint of determining initial tolerance, safety or pharmacokinetic information in single dose, single ascending dose, multiple dose or multiple ascending dose regimens, as described in 21 C.F.R. § 312.21(a) (or its successor regulation) or the equivalent thereof in any jurisdiction outside the U.S.
“Phase 2 Study” means a human clinical trial with the principal purpose being a determination of safety and efficacy in the target patient population over a range of doses and dose regimens, as described in 21 C.F.R. § 312.21(b) (or its successor regulation) or the equivalent thereof in any jurisdiction outside the U.S.
“Phase 2a Study” means a Phase 2 Study of a Product conducted by Licensee that is designed to demonstrate clinical “proof of concept” in a particular Indication.
“Phase 2b Study” means a controlled Phase 2 Study of a Product conducted by Licensee that is designed to determine the optimal dose for administration in a Phase 3 Study.
“Phase 3 Study” means a human clinical trial of a compound or product for an Indication on a sufficient number of subjects that is designed to establish with statistical significance that such compound or product is safe and efficacious for its intended use, and to determine contraindications, warnings, precautions and adverse reactions that are associated with the compound or product in the dosage range to be prescribed, and to support regulatory approval of such compound or product for such Indication or label expansion of such compound or product, as described in 21 C.F.R. § 312.21(c) (or its successor regulation) or the equivalent thereof in any jurisdiction outside the U.S..
“PMDA” means the Pharmaceutical and Medical Device Agency who with the PFSB regulate, review and approve drugs and medical devices in Japan.
“Pricing and Reimbursement Approval” means (a) the governmental approval, agreement, determination or decision establishing prices or value for a Product that can be charged in regulatory jurisdictions where the applicable Governmental Authorities approve or determine the price of pharmaceutical products, and (b) the approval, agreement, determination or decision recommending or approving a Product for use or establishing the prices for a Product that can be reimbursed in regulatory jurisdictions where the applicable Governmental Authority or Non-Governmental Authority approves, determines, or recommends the reimbursement or use of pharmaceutical products; provided, that in all cases [***]. 
“Product” means any pharmaceutical product preparation (including any and all forms, presentations, dosages, and formulations) for use for any and all diseases in the Field containing any Compound as the active pharmaceutical ingredient, in any mode of administration, alone or in combination with any other active agent, including any new dosage strengths, presentations, formulations, methods of administration and line extensions.
“Program” means the Development and Commercialization of one or more Products.
“Prosecution and Maintenance” has the meaning set forth in Section 9.3(a).
“Reference Product” has the meaning set forth in the definition of Generic Product.
“Registrational Study” means a human clinical trial that is intended (as of the time the clinical trial is initiated) to obtain sufficient data and results to support the filing of an application 
9

for Drug Approval of a compound or product, which may include a Phase 2b Study or a Phase 3 Study.  
“Regulatory Approval” means (a) Drug Approval and all other approvals necessary for the commercial sale of a Product in a given country or regulatory jurisdiction; and (b) Pricing and Reimbursement Approval (but only in those countries or regulatory jurisdictions where Pricing and Reimbursement Approval is required by Law for commercial sale).
“Regulatory Authority” means, in a particular country or jurisdiction, any applicable Governmental Authority or Non-Governmental Authority involved in granting Regulatory Approval in such country or jurisdiction.
“Regulatory Exclusivity” means any exclusive marketing rights or data exclusivity rights conferred by any Regulatory Authority with respect to a Product in a country or jurisdiction in the Territory, other than a Patent, that limits or prohibits a Person from (i) relying on pivotal safety or efficacy data generated with respect to a Product in an application for Regulatory Approval of a Generic Product or (ii) Commercializing a Generic Product, [***]. 
“Regulatory Materials” means regulatory applications, request, Information exchanges submissions, notifications, communications, correspondence, registrations, INDs, Drug Approvals, or other filings made to, received from, or otherwise conducted with, a Regulatory Authority to Exploit any Product in a particular country or jurisdiction.
“Royalty Term” has the meaning set forth in Section 8.3(b).
“SEC” has the meaning set forth in Section 12.4(d).
“Section 365(n)” means Section 365(n) of the U.S. Bankruptcy Code or analogous provisions of the bankruptcy laws of any Governmental Authority.
“Selling Party” has the meaning set forth in the definition of Net Sales. 
“STING Inhibitor License” has the meaning set forth in Section 2.1(a).
“[***] Consideration” means, with respect to any [***], all consideration received by Licensee and its Affiliates from the [***] that is directly allocable to the grant or exercise of the applicable [***].
“Sublicensee” means any entity, other than an Affiliate of Licensee, to whom Licensee assigns, grants, conveys, licenses, or transfers any rights to research, Develop, Commercialize, manufacture, or otherwise Exploit a Product.
“Term” has the meaning set forth in Section 13.1.
“Territory” means all countries and territories in the world. 
“Territory Infringement” has the meaning set forth in Section 9.3(a).
“Third Party” means any entity other than Licensor or Licensee or an Affiliate of either of them, or any contractor. 
“Third Party Patent Claim” has the meaning set forth in Section 9.4.
10

“U.S.” means the United States of America, including all possessions and territories thereof.
“Valid Claim” means a claim of any issued and unexpired Patent whose validity, enforceability, or patentability has not been affected by (a) irretrievable lapse, abandonment, revocation, dedication to the public, or disclaimer or (b) a holding, finding, or decision of invalidity, unenforceability, or non-patentability by a court, Governmental Authority, national or regional patent office or other appropriate body that has competent jurisdiction, such holding, finding, or decision being final and unappealable, or unappealed within the time allowed for appeal (other than a petition to the United States Supreme Court for a writ of certiorari).
ARTICLE 2
LICENSES GRANTS
2.1STING Inhibitor License.
(a)Subject to the terms and conditions of this Agreement, Licensor hereby grants to Licensee an exclusive (even as to Licensor) royalty-bearing license, with the right to grant sublicenses as permitted herein, under the Licensor Technology to Exploit Compounds and Products in the Field in the Territory (the “STING Inhibitor License”).
(b)Licensee, at its sole discretion, may grant sublicenses under the STING Inhibitor License through multiple tiers to any Affiliate or Third Party without the approval of Licensor; provided, that in all events (i) Licensee shall remain responsible for the performance of its Sublicensees hereunder and must not grant any rights that are inconsistent with the rights granted to and obligations of Licensee hereunder; and (ii) Licensee shall, upon Licensor’s written request, provide Licensor with a copy of any sublicense agreement, which may be redacted by Licensee to protect confidential or proprietary information that is not required for Licensor to confirm amounts of [***] Consideration, which copy shall be treated as Confidential Information of Licensee hereunder.
ARTICLE 3
EXCLUSIVITY
3.1Exclusivity. Unless otherwise agreed by the Parties in writing, Licensor and its Affiliates will not, directly or through any Third Party, Exploit in the Territory any Competitive Product in any field until the expiration or termination of this Agreement, [***]. For clarity, the provisions of this Section 3.1 shall continue to apply with respect to those Products and those jurisdictions where this Agreement remains in effect in the event of a partial termination of this Agreement. Notwithstanding the foregoing, in the event of a Change of Control of Licensor, nothing in this Section 3.1 shall be construed to limit or restrict the activities or operations of the Acquiror in such Change of Control or the Acquiror’s Affiliates (other than Licensor or any Affiliates of Licensor that existed prior to such Change of Control) with respect to any Competitive Product developed, manufactured or commercialized by such Acquiror or such Affiliates prior to such Change of Control.  
ARTICLE 4
PRODUCT DEVELOPMENT
4.1Overview; Diligence. Subject to the terms and conditions of this Agreement, Licensee shall be solely responsible, at its sole cost and effort, for the Development of 
11

Compound(s) and Product(s) in the Field in the Territory. Licensee shall use Commercially Reasonable Efforts to [***].  
4.2Development Reports. On or before [***] of each Calendar Year, Licensee shall provide Licensor with a written report that summarizes, in reasonable detail, material Development activities performed during the preceding half-year on any covered Compound or Product. All such reports and information shall be solely owned by, and deemed the Confidential Information of, Licensee.
4.3Transfer of Licensor Technology. Promptly following the Effective Date, Licensor will promptly provide to Licensee, in the form reasonably requested by Licensee, all Licensed Know-How and other Information obtained or possessed by Licensor or any of its Affiliates, its or their subcontractors, in each case, related to the Compounds and/or Products. Thereafter, from time to time during the Term or upon reasonable request by Licensee, Licensor shall promptly disclose and provide Licensee with access to additional Licensor Know-How and other Information as may be required for Licensee to exercise the rights and licenses granted to it, and to perform its obligations, under this Agreement.
ARTICLE 5
REGULATORY MATTERS
5.1Regulatory Responsibilities.
(a)As between the Parties, Licensee will be solely responsible for all regulatory submissions and exchanges and will direct and control all regulatory activities with respect to Compounds and Products in the Territory, including responses and correspondence, safety reporting, negotiation, analysis, and strategy. Licensor represents and warrants to Licensee that, as of the Effective Date, there are no Regulatory Materials in Licensor’s possession or under Licensor’s Control related to any Compound or Product. If, during the Term, the Parties become aware of any such Regulatory Materials in Licensor’s possession or under Licensor’s Control, Licensor will, promptly notify Licensee, and at Licensee’s request, promptly transfer all such Regulatory Materials to Licensee. 
(b)Licensee will be the primary interface with and will otherwise handle all correspondence, meetings, and other interactions with the relevant Regulatory Authorities concerning regulatory or other activities related to Compounds or Products in the Field in the Territory. Licensee will prepare and file any and all Regulatory Materials for each Compound or Product in the Field in the Territory [***]. Licensor will assist and cooperate, in a timely manner, [***], with Licensee in connection with the preparation and filing of such Regulatory Materials, as reasonably requested by Licensee. Such cooperation will include promptly responding within procedural or other timelines set by Regulatory Authorities or any applicable Law to any reasonable request from Licensee for Licensor Know-How or other Information needed for the Regulatory Materials.
(c)Unless the Parties otherwise agree in writing: (i) except as expressly contemplated by this Section 5.1, Licensor will not communicate with respect to any Compound or Product in the Field with any Regulatory Authority having jurisdiction in the Territory, unless so ordered by such Regulatory Authority, or required by applicable Law, in which case Licensor will provide prompt (but in any event within [***] Business Days) notice to Licensee of such order, or upon realizing such requirement is imposed by Law, and all details thereof; and (ii) except as expressly contemplated by this Section 5.1, Licensor will not submit any Regulatory Materials or seek Regulatory Approvals by or for itself for any Compound or Product in the Field in the Territory.
12

5.2Ownership of Regulatory Materials and Regulatory Approvals. All Regulatory Approvals in the Territory for Commercialization of the Compounds or Products in the Field in the Territory shall be in the name of Licensee (or its Affiliates or Sublicensees), and Licensee (or its Affiliates or Sublicensees) shall own all right, title and interest in all such Regulatory Approvals and all related Regulatory Materials. 
5.3Regulatory Costs. As between the Parties, Licensee will pay [***] of its costs and expenses related to the preparation, filing, and maintenance of all Regulatory Materials and Regulatory Approvals for each Product in the Field in the Territory. During the Term, Licensor will provide Licensee with access, [***], to all Licensor Know-How then in existence and in Licensor’s possession, including, where applicable, any pre-clinical or clinical data, CMC Information and manufacturing data, or the like, relating to any Compound or Product, or that would otherwise be reasonably helpful to Licensee in the Development of a Compound or Product. Licensor will support Licensee, as reasonably requested by Licensee and at [***], in obtaining and maintaining Regulatory Approvals in the Territory, including providing necessary documents, Information and other materials required by Laws or that would be reasonably useful in Licensee’s opinion to obtain (and maintain) Regulatory Approval(s) in the Territory, all in accordance with the terms and conditions of this Agreement.
ARTICLE 6
MANUFACTURE AND SUPPLY
6.1Supply Agreements. Licensor will, within [***] days after the Effective Date, enable and assist Licensee to enter into an agreement with each existing Third-Party manufacturer of the Compound(s) or Product(s), or assign to Licensee any such existing agreements between Licensor and Third Party manufacturers, in each case, to the extent applicable and if desired by Licensee.  
6.2Transfer of Inventory, Materials and Information. Licensor will, within [***] days after the Effective Date, transfer [***] to Licensee, Licensor’s (a) [***], (b) [***]; and (c) [***]. Licensor represents and warrants to Licensee that, as of the Effective Date, there are no Compounds or Products (including bulk active pharmaceutical ingredients) that have been [***]. Exhibit C sets forth a substantially complete list of [***] existing as of the Effective Date to be transferred by Licensor to Licensee in accordance with Section 4.3 and this Section 6.2.
ARTICLE 7
COMMERCIALIZATION
7.1Overview. Subject to the terms and conditions of this Article 7, as between the Parties, Licensee will be solely responsible for all aspects of the Commercialization of Products in the Field in the Territory. Licensee shall bear [***] costs and expenses incurred in connection with such Commercialization activities.
7.2Diligence. Upon obtaining Regulatory Approval of a Product in a Major Market Country, Licensee will use Commercially Reasonable Efforts to Commercialize such Product in the approved Indication in such Major Market Country. Notwithstanding anything herein to the contrary, Licensee’s commitment to use Commercially Reasonable Efforts as set forth herein shall not preclude the suspension or discontinuance of the Development or Commercialization of any Product, if appropriate, based on the application of Commercially Reasonable Efforts or Licensee’s assessment of the market conditions in any Major Market Country during the Term of this Agreement. Licensor hereby acknowledges and agrees that Licensee and its Affiliates make (and have made) no covenant, representation, or warranty, either express or implied, at Law or in 
13

equity, that they will be able to successfully achieve the Milestones, or that they will be able to achieve any amount of Net Sales, and Licensor specifically disclaims that it is relying upon or has relied upon any such covenants, representations or warranties that may have been made by any individual or entity. Nothing in this Agreement shall limit or restrict the right of Licensee or its Affiliates to Develop, make regulatory filings, obtain Regulatory Approvals with respect to, or Commercialize any product or to engage in any business or other activity.
7.3Pricing. Licensee will determine all pricing and related aspects including but not limited to discounting, rebating and the like of Products in the Field in the Territory. For the avoidance of doubt, Licensor does not have any right to [***] pricing or related activities surrounding the pricing of Products in the Field in the Territory.
ARTICLE 8
FINANCIALS
8.1Upfront Consideration. Licensee will pay to Licensor, within [***] days following the Effective Date, a one-time, non-refundable upfront fee of Two Million Dollars ($2,000,000) in cash.
8.2Milestone Payments. In addition to the consideration set forth in Section 8.1:
(a)Development/Regulatory Milestone Payments. Licensee will pay the following one-time Development/regulatory milestone payments (the “Development/Regulatory Milestones”) to Licensor, each within [***] days after the first achievement of each Development/Regulatory Milestone Event with respect to the Product set forth in the table below. For the avoidance of doubt, the payments set forth in the column headed “Product Payments” will be made upon the first achievement of the applicable Development/Regulatory Milestone Event with respect to a Product. Each such payment will be made in cash, in Dollars.
									
	No.	Development/Regulatory Milestone Event	Product Payments
	[***]
	[***]
	[***]

	[***]
	[***]
	[***]

	[***]
	[***]
	[***]

	[***]
	[***]
	[***]

	[***]
	[***]
	[***]

	[***]
	[***]
	[***]

	[***]
	[***]
	[***]

14

									
	[***]
	[***]
	[***]

	[***]
	[***]
	[***]

	[***]
	[***]
	[***]

	[***]
	[***]
	[***]

	[***]
	[***]
	[***]

	[***]
	[***]
	[***]

	[***]
	[***]
	[***]

	[***]
	[***]
	[***]

	[***]
	[***]
	[***]

	[***]
	[***]
	[***]

	[***]
	[***]
	[***]

	[***]
	[***]
	[***]

The Development/Regulatory Milestone payments are payable only once with respect to the Products. For clarity, this means that the total maximum amount of Development/Regulatory Milestone payments payable assuming achievement of all Development/Regulatory Milestones is [***].
(b)First Subject Dosing in the U.S.  In the event that the [***] does not occur on or before [***], whether conducted by Licensee or any or its Affiliates or Sublicensees, then Licensee shall make a one-time, non-refundable payment of [***] in cash to Licensor within [***] following [***]. 
(c)Net Sales Milestone Payments. Licensee will pay the following one-time Net Sales milestone payments (the “Net Sales Milestones”) to Licensor when the aggregate Net Sales of a Product in the Territory in any Calendar Year first reach the specified amount listed in the “Net Sales Milestone Event” column in the table below. For the avoidance of doubt, the payments set forth in the column headed “Product Payments” will be made upon the first achievement of the applicable Net Sales Milestone Event with respect to a Product. For the further avoidance of doubt, in calculating aggregate annual Net Sales of a Product for purposes 
15

of this Section 8.2 (c) and Section 8.3(a), Products containing [***] will be deemed the same Product. Licensee will notify Licensor in writing within [***] days after the end of the Calendar Quarter in which the applicable Net Sales Milestone Event is achieved and payment shall accompany [***]. Each such payment shall be made in cash, in Dollars.
									
	No.	Net Sales Milestone Event	Product Payments
	[***]
	[***]
	[***]

	[***]
	[***]
	[***]

	[***]
	[***]
	[***]

	[***]
	[***]
	[***]

	[***]
	[***]
	[***]

The Net Sales Milestone payments are payable only once with respect to the Products. For clarity, this means that the total maximum amount of Net Sales Milestone payments payable assuming achievement of all Net Sales Milestones is [***]. 
8.3Royalties.
(a)Royalty Rates. Licensee will pay to Licensor royalties on Net Sales in the Territory during the Royalty Term for each Product, as calculated by multiplying the applicable royalty rate set forth below (subject to reductions as set forth herein) by the corresponding amount of incremental, aggregated Net Sales of all such Product, as applicable, in the Territory in such Calendar Year. For the avoidance of doubt, the royalty rates set forth in the column headed “Product Royalty Rates” will be paid on Net Sales of all such Product. 
						
	Annual Net Sales in the Territory	Product Royalty Rates
	[***]
	[***]

	[***]
	[***]

	[***]
	[***]

	[***]
	[***]

16

(b)Royalty Term. Licensee will pay to Licensor royalties on Net Sales of Products under this Section 8.3 [***] basis during the period commencing on [***] and ending on [***] (the “Royalty Term”). Upon expiration of the Royalty Term with respect to a Product in a given country, the license granted to Licensee pursuant to Article 2 will become a fully paid-up and royalty-free license for such Product in such country. 
(c)Royalty Reductions. 
(i)Valid Claim Coverage. In any Calendar Quarter in which a Product is not Covered by a Valid Claim of a Licensor Patent in a country where such Product is sold but such Product has Regulatory Exclusivity in such country, the applicable royalty rate set forth in Section 8.3(a) with respect to such Product and such country shall be reduced by [***], subject to Section 8.3(d). 
(ii)Valid Claim and Regulatory Exclusivity Coverage. In any Calendar Quarter in which a Product is not Covered by a Valid Claim of a Licensor Patent in a country where such Product is sold and such Product does not have Regulatory Exclusivity in such country, the applicable royalty rate set forth in Section 8.3(a) with respect to such Product and such country shall be reduced by [***], subject to Section 8.3(d).
(iii)Generic Products. If, with respect to any Product in any country, sales of Generic Products account for [***] or more of the aggregate combined sales, on a unit basis, of such Product and such Generic Products in such country in a Calendar Quarter, as determined by reference to sales data obtained from a reputable independent source (e.g., IQVIA), then for the remainder of the Royalty Term for such Product in such country, the applicable royalty rate set forth in Section 8.3(a) with respect to such Product and such country shall be reduced by [***], subject to Section 8.3(d).
(iv)Third Party Payments. If Licensee reasonably determines that it is necessary to seek or obtain a license from any Third Party to Exploit a Product in any country in the Territory, then Licensee may offset against royalties otherwise due to Licensor under this Agreement with respect to such country an amount equal to [***] of any royalties or other license fees/payments actually paid by Licensee to such Third Party under such license, subject to Section 8.3(d).
(d)Royalty Floor. In no event will the royalties payable by Licensee in any Calendar Quarter with respect to any Product in a given country be reduced by more than an aggregate [***] as a result of the royalty reductions set forth in Section 8.3(c). Notwithstanding the foregoing, any excess amounts that would have otherwise been deducted in such Calendar Quarter pursuant to Section 8.3(c) shall be deducted from royalties otherwise due to Licensor under this Agreement with respect to such Product and such country in successive Calendar Quarters until the credit has been realized in full. 
(e)Royalty Reports and Payments. Within [***] days following the end of each Calendar Quarter commencing with the Calendar Quarter in which the First Commercial Sale of any Product is made anywhere in the Territory, Licensee shall provide Licensor with a report containing the following information for such Calendar Quarter, on a [***] basis: [***]. If and to the extent that Licensee identifies an error in a prior royalty report, it shall set forth the error and related calculations in the current royalty report. Concurrent with the delivery of the applicable quarterly royalty report, Licensee shall pay [***] to Licensor pursuant to this Section 8.3 with respect to Net Sales by Licensee, its Affiliates and their respective Sublicensees for such Calendar Quarter.
17

8.4[***] Consideration.  
(a)Payment Amounts. Licensee will pay to Licensor [***] Consideration received by Licensee or its Affiliates pursuant to any [***] by Licensee for [***]. If such [***] is [***] prior to initiation (i.e., [***]) of [***], such percentage will be [***]; if such [***] is entered into after initiation (i.e., [***]) of [***], the percentage will be [***].  
(b)Reports and Payments. Within [***] days following execution by Licensee of any [***], Licensee will provide to Licensor a true and complete copy of such [***], which may be [***] to protect confidential or proprietary information that is not reasonably necessary for Licensor to confirm the amounts of [***] Consideration. Within [***] days following the end of each Calendar Quarter in which Licensee has received [***] Consideration, Licensee will provide Licensor with a report [***] Consideration received and a calculation of the payment due to Licensor pursuant to Section 8.4(a), which payment [***].
8.5Foreign Exchange. Conversion of sales recorded in local currencies to Dollars will be calculated, on a quarterly basis, using the average of the buying and selling rates on the last [***] Business Days of the Calendar Quarter to which such amounts pertain, as published by The Wall Street Journal, Internet Edition at www.wsj.com. 
8.6Payment Method; Late Payments. All amounts specified in this Agreement are in Dollars and all cash payments by one Party to the other Party under this Agreement shall be paid in Dollars by wire transfer of immediately available funds into an account designated by the Party that is owed such payment (such Party, the “Payee”). If the Payee does not receive payment of any sum due to it on or before the due date, simple interest will thereafter accrue on the sum due to the Payee until the date of payment at the per annum rate of [***], or the maximum rate allowable by Laws, whichever is lower. Notwithstanding the foregoing, a Party making a payment (the “Payor”) pursuant to this Agreement shall not be deemed to have made a late payment, and no interest shall be due pursuant to this Section 8.6, if the payment is not made by the due date as a result of the Payee’s efforts to reduce or eliminate a tax applicable to such payment pursuant to Section 8.9(c) solely upon and pursuant to the request of the other Party, provided the Payor makes the required payment (net of applicable withholding taxes) as soon as practicable after the tax issue is resolved.
8.7Records. Each Party will keep (and will ensure that its Affiliates and sublicensees keep) such records as are required to determine, in accordance with GAAP or international financial reporting standards, as applicable, and this Agreement, the sums or credits due under this Agreement, including Net Sales and [***] Consideration. Each Party will retain all such books, records and accounts until the later of (a) [***] years after the end of the period to which such books, records and accounts pertain and (b) the expiration of the applicable tax statute of limitations (or any extensions thereof), or for such longer period as may be required by Laws. Each Party will require its sublicensees to provide to it a report detailing the foregoing expenses and calculations incurred or made by such sublicensee, which report will be made available to the other Party in connection with any audit conducted by such other Party pursuant to Section 8.8.
8.8Audits. Each Party may have an independent regional or national certified public accounting firm, reasonably acceptable to the audited Party, have access during normal business hours, and upon reasonable prior written notice, to examine only those records of the audited Party (and its Affiliates and sublicensees) as may be reasonably necessary to determine, with respect to any Calendar Year ending not more than [***] years before such Party’s request, the correctness or completeness of any report or payment made under this Agreement; provided, however, the audited Party shall not be required to provide, and neither the auditing Party nor the independent certified public accountant engaged by the auditing Party shall be entitled to review, 
18

the tax returns or tax records of the audited Party or those of its Affiliates and sublicensees. The foregoing right of review may be exercised only once per year and only once with respect to each such periodic report and payment. Reports of the results of any such examination will be (a) limited to details of any discrepancies in the audited Party’s records relating to Product together with an explanation of the discrepancy and the circumstances giving rise to the discrepancy (b) made available to both Parties and (c) subject to Article 12. If the audit report concludes that (i) additional amounts were owed by the audited Party, the audited Party will pay the additional amounts, with interest from the date originally due as provided in Section 8.6 or (ii) excess payments were made by the audited Party, the auditing Party will reimburse such excess payments, without interest, in either case ((i) or (ii)), within [***] days after the date on which such audit report is delivered to both Parties. The Party requesting the audit will bear the full cost of the performance of any such audit, unless such audit, which covers the entire Calendar Year, discloses a variance to the detriment of the auditing Party of more than [***] from the amount of the original report, royalty or payment calculation, in which case the audited Party will bear the full cost of the performance of such audit. The results of such audit will be final, absent manifest error. 
8.9Taxes.
(a)Taxes on Income. Each Party will pay all taxes (including related interest and penalties) imposed on its share of income arising directly or indirectly from the efforts of, or the accrual, receipt or deemed receipt of any payment by, such Party under this Agreement.
(b)Tax Withholding. If any taxes (including related interest and penalties) are required by Laws to be withheld by a Party with respect to an amount payable to the other Party, such Party will: (a) withhold such taxes from the payment made to the other Party; (b) timely pay the withheld taxes to the proper taxing authority; (c) send proof of payment to the other Party; and (d) reasonably assist the other Party in its efforts to obtain a refund of or credit for such tax payment in accordance with Section 8.9(c). Any amount actually withheld and remitted by a Party to a taxing authority pursuant to this Section 8.9(b) will be treated for all purposes of this Agreement as paid to the other Party. If a Party makes a payment without deduction for tax withholding and an amount of tax should have been withheld from such payment, the Party that made such payment shall be entitled to recover the under-withheld tax (and any penalties, additions to tax and interest related thereto and any penalties, additions to tax and interest payable by the paying Party due to the failure to timely withhold) by an additional withholding from any amount payable to the other Party under this Agreement, and to the extent such recovery is insufficient, such Party may make a claim pursuant to ARTICLE 11. No amount shall be withheld, or a reduced amount shall be withheld, as applicable, if, in accordance with Section 8.9(c), a Party that is entitled to a payment timely furnishes the other Party with the necessary tax forms and other documents prescribed by applicable Laws, which shall be in a form reasonably satisfactory to the Party receiving the documents, identifying that the relevant payment is exempt from tax or subject to a reduced tax rate.
(c)Tax Cooperation. The Parties agree to cooperate with one another and use reasonable efforts to reduce or eliminate tax withholding or similar obligations in respect of royalties, milestone payments, and other payments made by one Party to the other Party under this Agreement. The Party entitled to a payment will provide the paying Party with any tax forms that may be reasonably necessary in order for the paying Party not to withhold tax or to withhold tax at a reduced rate under an applicable bilateral income tax treaty or other applicable Laws. Each Party will provide the other with reasonable assistance to enable the recovery, as permitted by Law, of withholding taxes, value added taxes, or similar obligations resulting from payments made under this Agreement, such recovery to be for the benefit of the Party bearing such withholding tax or value added tax. 
19

ARTICLE 9
INTELLECTUAL PROPERTY MATTERS
9.1Ownership of Inventions. 
(a)Licensor Technology. As between the Parties, Licensor shall solely own any Licensor Technology. 
(b)New Inventions. As between the Parties, Licensee shall own all rights, title and interest in or to any new discoveries, improvements, or inventions conceived, discovered, developed or otherwise made by or on behalf of Licensee, its Affiliates or its Sublicensees after the Effective Date and during the Term, in each case, in connection with the Exploitation of the Products or performance of activities under this Agreement, whether or not patented or patentable, and any and all Patents and other intellectual property rights with respect thereto. 
9.2Prosecution of Patents.
(a)Subject to Section 9.2(b) with respect to a Licensor Patent, as between the Parties, Licensee will have the exclusive right to prepare, file, prosecute and maintain the Licensor Patents, including handling re-examinations and reissues together with the conduct of interferences, derivation proceedings, pre-and post-grant opposition proceedings, post-grant patent proceedings (such as inter partes review and post grant review) (collectively, the “Prosecution and Maintenance”). As between the Parties, [***] incurred after the Effective Date only in connection with the Prosecution and Maintenance of any Licensor Patent that it chooses to Prosecute and Maintain in the Territory. Before any substantive prosecution filing, Licensee will provide Licensor with a reasonable opportunity to review and comment on such prosecution efforts regarding the Licensor Patents as follows: Licensee will provide Licensor with copies of all material communications from any patent authority regarding the Licensor Patents, and will provide Licensor, for its review and comment, with drafts of any material filings or responses to be made to such patent authorities in a reasonable amount of time in advance of submitting such filings or responses. Licensee will consider in good faith any reasonable comments thereto provided by Licensor in connection with the prosecution of the Licensor Patents. Each Party will provide the other Party all reasonable assistance and cooperation (at the other Party’s cost) in the Prosecution and Maintenance efforts of any Licensor Patent provided in this Section 9.2(a), including executing any other required documents or instruments for such filings, Prosecution and Maintenance. 
(b)If Licensee decides not to Prosecute and Maintain, or to abandon, any Licensor Patent anywhere in the Territory without having first filed a substation Patent application, Licensee will promptly notify Licensor and Licensor may assume Licensee’s rights and responsibilities under this Section 9.2(a) with respect to such Licensor Patent, and in connection with assuming such rights and responsibilities, including responsibility for costs, Licensor may Prosecute and Maintain such Licensor Patent in the Territory, and unless Licensee reimburses all of Licensor’s documented out-of-pocket costs to Prosecute and Maintain such Patent after issuance, such Patent shall thereafter be excluded from the definition of “Licensor Patents” for purposes of the applicable license grant in Article 2. 
(c)As between the Parties, Licensee shall have the sole right to conduct, and be solely responsible for, the Prosecution and Maintenance of any Licensee Patents, at Licensee’s cost and expense. 
(d)As between the Parties, Licensee will be solely responsible for deciding on strategy, selecting which Licensor Patent(s) to involve, and obtaining patent term restoration in 
20

any country in the Territory under any statute or regulation equivalent or similar to 35 U.S.C. §156, where applicable to the Product, and will have the sole right to obtain patent term extensions (including any available pediatric extensions) or supplemental protection certificates or their equivalents in any country with respect to a Licensee Patent. With respect to data exclusivity periods (such as those periods listed in the FDA’s Orange Book (including any available pediatric extensions) or periods under national implementations of Article 10.1(a)(iii) of Directive 2001/EC/83 or orphan exclusivity periods, and all equivalents in any country), Licensee shall have the sole and exclusive right to seek and maintain all such data exclusivity periods available for the Products. With respect to all of the rights and activities identified in this Section 9.2, Licensor hereby appoints Licensee as its agent for such purposes with the authority to act on Licensor’s behalf with respect to any Licensor Patent in a manner consistent with this Agreement.
9.3Patent Enforcement.
(a)If either Party becomes aware of any existing or threatened infringement of any of the Licensor Patents in the Field anywhere in the Territory by a Third Party, including any declaratory judgment, attempt at injunctive or other equitable relief, and opposition, post-grant administrative proceedings, or similar action from a Third Party alleging the invalidity, unenforceability, or non-infringement of any of the Licensor Patents (“Territory Infringement”), such Party will promptly notify the other Party in writing to that effect and the Parties will consult and cooperate with each other regarding any actions to be taken with respect to such Territory Infringement. For any Territory Infringement, each Party will share with the other Party all Information available to it regarding such actual or alleged infringement.
(b)Subject to Section 9.3(c) with respect to a Licensor Patent, as between the Parties, Licensee shall have the exclusive right to bring an appropriate suit or other action against any person or entity engaged in or threatening any such Territory Infringement which infringes (or would infringe) any Licensor Patent that includes claims directed to any Product, at Licensee’s cost and expense. Licensor will take appropriate and timely action to enable Licensee to commence a suit or petition for equitable relief or take the actions set forth in the preceding sentence. 
(c)If Licensee fails to commence a suit or initiate equitable relief to enforce against such Territory Infringement or to settle or otherwise secure the abatement of such Territory Infringement, in each case, with respect to an applicable Licensor Patent within [***] days after becoming aware of such Territory Infringement, then Licensor may commence a suit or take other action to enforce such Licensor Patent against such Territory Infringement at its own cost and expense. In this case, Licensee will take appropriate reasonable and timely actions to enable Licensor to commence a suit or take the other actions set forth in the preceding sentence. 
(d)As between the Parties, Licensee shall have the sole right, at [***], to enforce against any infringement of a Licensee Patent, including any declaratory judgment, attempt at injunctive or other equitable relief, and opposition, post-grant administrative proceedings, or similar action from a Third Party alleging the invalidity, unenforceability, or non-infringement of any of the Licensee Patent. 
(e)Each Party will provide to the enforcing Party reasonable and timely assistance in such enforcement, at such enforcing Party’s request and expense, including executing all necessary and proper documents and if required to establish and maintain standing to join such action as a party plaintiff if required by Law to pursue such action, provided that the Party so joined as a party plaintiff shall be under no obligation to participate except to the extent that such participation is required as the result of its being a named party to such action or by 
21

applicable Laws, and the enforcing Party agrees to fully indemnify, defend and hold harmless the other Party from and against all Claims (including reasonable legal fees and expenses) incurred by the other Party relating thereto. Each Party will additionally use Commercially Reasonable Efforts to have joined to such action as a party plaintiff any Third Party whose joinder is required by applicable Law to establish and maintain standing to pursue such action. The enforcing Party will keep the other Party regularly informed of the status and progress of such enforcement efforts, will reasonably consider the other Party’s comments on any such efforts. The non-enforcing Party may obtain separate legal representation in such matter by counsel of its own choice and at its own expense, but such Party will at all times cooperate fully with the enforcing Party, subject to the provisions of Section 9.3(f).
(f)Settlement. Licensor will not settle any claim, suit or action that it brought in respect of Territory Infringement with respect to any Licensor Patent in any manner that would negatively impact the applicable Licensor Patents or that would limit or restrict the ability of Licensee to Exploit any Compound or Product anywhere in the Territory in the Field, without the prior written consent of Licensee, which consent will not be unreasonably withheld, conditioned or delayed. Nothing in this Article 9 requires Licensee to consent to any settlement that is reasonably anticipated by Licensee to have a substantially adverse impact upon any Licensor Patent in the Territory, or to the Exploitation of any Compound or Product in the Territory. Licensee will not settle any claim, suit or action that it brought in respect of Territory Infringement that (i) includes any statement that may be used as an admission of invalidity or unenforceability of any Licensor Patents, or (ii) imposes any material obligations on Licensor or admits fault on behalf of Licensor, in each case without Licensor’s prior written consent, which consent shall not be unreasonably withheld, conditioned or delayed.
(g)Expenses and Recoveries. The enforcing Party bringing a claim, suit, or action in respect of Territory Infringement will pay for any expenses incurred by such Party as a result of such claim, suit, or action. If such Party recovers monetary damages in such claim, suit or action, such recovery will be allocated first to the reimbursement of any expenses incurred by the Parties in such litigation, and any remaining amounts will be retained as follows: (i) if Licensee is the enforcing Party, then [***], and (ii) if Licensor is the enforcing Party, then [***].
(h)Hatch Waxman Litigation. Notwithstanding anything herein to the contrary, should a Party receive a certification under 21 U.S.C. § 355 (j)(2)(A)(vii)(iv) and 21 C.F.R. § 314.94 (a)(12)(i)(A)(4) with respect to one or more Licensor Patents or Licensee Patents pursuant to the Drug Price Competition and Patent Term Restoration Act of 1984 (Public Law 98-417, known as the Hatch-Waxman Act), as amended, or its equivalent in a country other than the US, then such Party shall immediately provide the other Party with a copy of such certification. Licensee shall have [***] Business Days from the date on which it receives or provides a copy of such certification to provide written notice to Licensor (“Paragraph IV Notice”) whether Licensee will bring suit, at its expense, within a [***] day period from the date of such certification. Should such [***] Business Day period expire without Licensee providing such Paragraph IV Notice to Licensor or with written notification that Licensee has no intention to bring suit under the Hatch-Waxman Act, then Licensor shall be free to immediately bring suit in its name, but only with respect to any applicable Licensor Patents.
9.4Infringement of Third Party Rights. If a Product made, used, offered for sale or sold by Licensee, its Affiliates or Sublicensees, or the Licensor Technology becomes the subject of a Third Party’s claim or assertion of infringement of a Patent granted by a jurisdiction within the Territory (each such claim or assertion a “Third Party Patent Claim”), Licensee will promptly notify Licensor, or vice versa if the Licensor is notified first. and the Parties will work toward their shared, mutual interest in the outcome of such potential dispute, and thereafter, the Parties will promptly meet to consider the Third Party Patent Claim and the appropriate course of action. Licensee will defend any such Third Party Patent Claim; provided that the provisions of 
22

Section 9.3 govern the right of Licensee to assert a counterclaim of infringement of any Licensee Patent or any Licensor Patent. Notwithstanding the above, Licensee shall not enter into any settlement of any Third Party Patent Claim that would (a) require [***], or (b) [***], in each case ((a) or (b)), without Licensor’s prior written consent, which consent shall not be unreasonably withheld, conditioned or delayed.
9.5Patent Marking. Licensee and its Affiliates and Sublicensees will mark any Product marketed and sold by Licensee or its Affiliates or Sublicensees hereunder with appropriate patent numbers or indicia; provided, however, that Licensee will only be required to so mark such Product (a) [***] or (b) as otherwise required by applicable Law.
9.6Packaging; Trademarks. Licensee will have the [***] right to [***] of Product for use in the Territory and may [***] of Products in the Territory and [***]. 
ARTICLE 10
REPRESENTATIONS AND WARRANTIES; COVENANTS
10.1Licensee Representations, Warranties and Covenants. Licensee represents, warrants, and covenants to Licensor, as of the Effective Date, as follows:
(a)Due Organization. It is a corporation duly organized, validly existing and in good standing under the Laws of the jurisdiction in which it was incorporated.
(b)Power, Authority and Binding Agreement. 
(i)Licensee has the power and authority to enter into this Agreement and perform its obligations hereunder;
(ii)Licensee has taken all necessary action on its part required to authorize the execution and delivery of this Agreement and the performance of its obligations hereunder; and
(iii)This Agreement has been duly executed and delivered on behalf of Licensee, and constitutes a legal, valid and binding obligation of Licensee that is enforceable against it in accordance with its terms, subject to bankruptcy, insolvency, reorganization, moratorium or similar Laws affecting or relating to the enforcement of creditors’ rights generally, and to general principles of equity.
(c)No Conflict. The execution and delivery of this Agreement by Licensee and the performance of Licensee’s obligations hereunder do not conflict with or violate, or constitute a breach of or default under, (i) any applicable Laws, (ii) Licensee’s certificate of incorporation or by-laws, or (iii) any material contract to which Licensee is a party or by which it is bound.
(d)Other Rights. Neither Licensee nor any of its Affiliates is a party to or otherwise bound by any contract or agreement that will result in any other person obtaining any interest in, or that would give to any other person any right to assert any claim in or with respect to, any of Licensee’s rights under this Agreement.
(e)No Violation. Neither Licensee nor any of its Affiliates is under any obligation to any person, contractual or otherwise, that is in violation of the terms of this Agreement or that would impede the fulfillment of Licensee’s obligations hereunder.
23

(f)No Debarment. Neither Licensee nor any of its Affiliates is debarred or suspended or excluded under the FD&C Act or by the analogous Laws of any Regulatory Authority.
10.2Licensor Representations, Warranties and Covenants. Licensor represents, warrants, and covenants to Licensee, as of the Effective Date, as follows:
(a)Due Organization. It is a company or corporation duly organized, validly existing, and in good standing under the Laws of the jurisdiction in which it was incorporated or formed.
(b)Power, Authority and Binding Agreement. 
(i)It has the power and authority and the legal right to enter into this Agreement and perform its obligations hereunder; 
(ii)It has taken all necessary action on its part required to authorize the execution and delivery of this Agreement and the performance of its obligations hereunder; and
(iii)This Agreement has been duly executed and delivered on behalf of Licensor, and constitutes a legal, valid and binding obligation of Licensor that is enforceable against it in accordance with its terms, subject to bankruptcy, insolvency, reorganization, moratorium or similar Laws affecting or relating to the enforcement of creditors’ rights generally, and to general principles of equity.
(c)No Conflict. The execution and delivery of this Agreement by Licensor, the performance of Licensor’s obligations hereunder, and the grant by Licensor of the licenses and sublicenses granted hereunder do not and will not conflict with or violate, or constitute a breach of or default under, (i) any applicable Laws; (ii) Licensor’s certificate of incorporation, by-laws or equivalent organizational documents; or (iii) any material contract to which Licensor is a party or by which it is bound.
(d)Other Rights. Neither Licensor nor any of its Affiliates is a party to or otherwise bound by any contract or agreement that will result in any other person obtaining any interest in, or that would give to any other person any right to assert any claim in or with respect to, any of Licensor’s rights under this Agreement.
(e)No Violation. Neither Licensor nor any of its Affiliates is under any obligation to any person, contractual or otherwise, that is in violation of the terms of this Agreement or that would impede the fulfillment of Licensor’s obligations hereunder. Neither Licensor nor any of its Affiliates are bound by any non-competition agreements related to any Compound or Product. 
(f)No Debarment. Neither Licensor nor any of its Affiliates is debarred, suspended or excluded under the FD&C Act or by the analogous Laws of any Regulatory Authority.
(g)Licensor Patents. Exhibit A lists all Patents Controlled by Licensor anywhere in the Territory as of the Effective Date that Cover any Compound or Product. Licensor has complied with all Laws in connection with the prosecution and maintenance of the Licensor Patents and regulatory exclusivity, including the duty of candor owed to any patent office or Regulatory Authority pursuant to such Laws. All material renewal and maintenance fees due as of the Effective Date with respect to the prosecution and maintenance of the Licensor Patents have been paid by or for Licensor. The inventors named in the Licensor Patents are all of 
24

the true inventors for such Licensor Patents and each of such inventors has assigned to Licensor or its Affiliates all of his or her right, title and interest to such Licensor Patents and the inventions described therein, or if assignment is not allowed by applicable Law then issued an exclusive, non-royalty bearing, worldwide license to Licensor or its Affiliates.
(h)Title; Encumbrances. Licensor is the exclusive owner of all Licensor Patents and material Licensor Know-How, and has sufficient legal title and ownership or license rights in the Licensor Technology, free and clear of mortgages, pledges, liens, security interests, options, encumbrances, charges or claims of any kind, to grant the licenses to Licensee as purported to be granted pursuant to this Agreement. Licensor has not assigned, transferred otherwise granted any rights with respect to any Compound or Product in the Territory to any person or entity other than Licensee. 
(i)Validity. No Third Party has initiated or threatened in writing any legal action asserting that the Licensor Patents are invalid or unenforceable or that such Third Party has any rights thereto. Licensor has received no notice that any Third Party has taken any action before any patent and trademark office (or similar Governmental Authority), which, if successful, would render any of the Licensor Technology invalid or unenforceable or would otherwise in any way alter ownership rights of the Licensor. Licensor does not have knowledge of any Information which leads it to believe that any issued or pending Patents included in (or associated with) the Licensor Patents are invalid or unenforceable or that the Licensor’s ownership rights would be adversely impacted. 
(j)Non-Infringement. To the knowledge of Licensor, (i) no Third Party is infringing or has infringed the Licensor Technology or is misappropriating the Licensor Know-How; and (ii) the Development, manufacture and Commercialization of the Compounds and Products can be carried out in the manner contemplated by this Agreement without infringing any Patent or other intellectual property rights of any Third Party. Licensor has not received any written notice from any Third Party asserting or alleging that (i) the Exploitation of any Compound or Product before the Effective Date infringed or misappropriated the intellectual property rights of such Third Party or (ii) the exercise of Licensee’s rights as granted under this Agreement infringes or would infringe any Third Party intellectual property rights.
(k)No Proceedings. To the knowledge of Licensor, there are no pending, alleged or threatened, (i) inter partes reviews, post-grant reviews, interferences, re-examinations or oppositions involving the Licensor Patents that are in or before any patent authority (or other Governmental Authority performing similar functions) or (ii) inventorship challenges involving the Licensor Patents that are in or before any patent or other Governmental Authority.
(l)No Consents. Licensor possesses all permits, licenses, registrations, authorizations, orders and approvals required to (i) conduct its business as pertains to the Compounds and Products in compliance with Laws, and (ii) enter into and perform its obligations under this Agreement.
(m)Access to Information. Licensor has allowed, and will continue to allow, Licensee access to all material information in Licensor’s possession or control (i) containing [***]; (ii) concerning [***]; (iii) useful to [***]; and (iv) in respect of [***], all of which information (referred to in clauses (i), (ii) and (iii) above) is true and correct in all material respects. Licensor has disclosed to Licensee all material contracts relating to the Licensor Technology or the Development, manufacture or Commercialization of any Compound or Product and is not in material breach or default of any such material contracts.
(n)Confidentiality Obligations. All current and former employees and paid consultants of Licensor and its Affiliates who are or have been substantively involved in the 
25

conception, design, review, evaluation, reduction to practice, or Development of the Licensor Technology, any Compound or any Product have executed written contracts or are otherwise obligated to protect the confidential status and value thereof and to vest in Licensor exclusive ownership, or if prohibited by applicable Law, an exclusive, non-royalty bearing, worldwide license thereto of the Licensor Technology, any Compound and any Product. No Third Party has any Licensor Know-How in its possession or control which is not subject to continuing obligations of confidentiality owed to Licensor or its Affiliates for at least the duration of the Term. 
(o)Safety and Efficacy. Licensor is not aware of any problems, questions or challenges concerning the safety, tolerability or efficacy of any Compound or Product (including any of their ingredients) or of any questions raised by any Regulatory Authority with respect thereto, and Licensor has informed Licensee of all adverse drug reactions and other safety and tolerability matters known to Licensor relating to any Compound or Product or their use.
(p)Regulatory Matters.
(i)Licensor has provided or made available, when requested by Licensee to conduct its due diligence review, any and all documents and communications in its possession from and to any Governmental Authority, or prepared by any Governmental Authority, related to any Compound or Product, that may bear on the compliance with the requirements of any Governmental Authority, including any notice of inspection, inspection report, warning letter, notice of violation, deficiency letter, or similar communication;
(ii)Licensor and its Affiliates have conducted all research and Development of the Compound and Products in accordance with Laws;
(iii)Neither Licensor nor any of its Affiliates has received any oral or written communication (including any warning letter, notice of violation, deficiency letter, untitled letter, or similar notices, or other legal action) from any Governmental Authority, and there is no action pending or to Licensor’s knowledge threatened, in each case alleging that Licensor or any of its Affiliates has failed to comply with Laws in connection with the research and Development of any Compound or Product; and
(iv)To Licensor’s knowledge, none of Licensor, any of its Affiliates, or any of their respective officers, employees or agents has made, with respect to any Compound or Product, an untrue statement of a material fact to any Governmental Authority or failed to disclose a material fact required to be disclosed to such Governmental Authority.
(q)Assets and Revenues. Licensor does not have more than $184 million in either annual net sales or total assets for purposes of Section 18a(a)(2)(B)(ii) of the HSR Act. For purposes of this Section 10.2(s), the term “Licensor” shall include Licensor’s “ultimate parent entity” (as such term is defined in 16 C.F.R. § 801.1(a)(3)) and all entities included within Licensor’s ultimate parent entity.
10.3Covenants.
(a)No Debarment. In the course of its activities pursuant to this Agreement, neither Party will use any employee, consultant or contractor:
(i)who has been debarred, excluded or suspended under Section 306(a) or 306(b) of the FD&C Act, or other applicable provision(s) of U.S. Law, or pursuant to the analogous Laws of any Regulatory Authority;
26

(ii)who, to such Party’s knowledge, has been charged with, or convicted of, any felony or misdemeanor within the ambit of 42 U.S. C. §§ 1320a-7(a), 1320a-7(b)(l)-(3), or other applicable provision(s) of U.S. Law, or otherwise pursuant to the analogous Laws of any Regulatory Authority, or is proposed for exclusion, or the subject of exclusion or debarment or suspension proceedings by a Regulatory Authority, during the employee’s or consultant’s employment or contract term with such Party; or
(iii)who is excluded, suspended or debarred from participation, or otherwise ineligible to participate, in any U.S. or non-U.S. healthcare programs (or who has been indicted or convicted of a criminal offense that falls within the scope of 42 U.S. C. §1320a-7 or other relevant U.S. Laws but has not yet been excluded, debarred, suspended, or otherwise declared ineligible), or excluded, suspended or debarred by a Regulatory Authority from participation, or otherwise ineligible to participate, in any procurement or non-procurement programs.
Each Party will notify the other Party promptly, but in no event later than [***] Business Days, upon becoming aware that any of its employees or consultants has been excluded, debarred, suspended or is otherwise ineligible, or is the subject of exclusion, debarment or suspension proceedings by any Regulatory Authority.
(b)Compliance. Each Party and its Affiliates will comply in all material respects with all applicable Laws in the Territory where any Compound or Product is Exploited by or on behalf of such Party or its Affiliates, and in connection with their respective performance of its obligations under this Agreement, including where applicable the statutes, regulations and written directives of the FDA, the FD&C Act, and the U.S. Foreign Corrupt Practices Act of 1977 (15 U.S.C. §78dd-1 et seq.). 
(c)Third Party Confidentiality. Licensor will maintain the confidentiality of the Licensor Know-How and will ensure that no Third Party has any Licensor Know-How in its possession or Control which is not subject to continuing obligations of confidentiality owed to Licensor or its Affiliates for at least [***].
10.4No Other Representations or Warranties. EXCEPT AS EXPRESSLY STATED IN THIS AGREEMENT, NO REPRESENTATIONS OR WARRANTIES WHATSOEVER, WHETHER EXPRESS OR IMPLIED, INCLUDING WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, NON-INFRINGEMENT, OR NON-MISAPPROPRIATION OF THIRD PARTY INTELLECTUAL PROPERTY RIGHTS, ARE MADE OR GIVEN BY OR ON BEHALF OF A PARTY, AND ALL REPRESENTATIONS AND WARRANTIES, WHETHER ARISING BY OPERATION OF LAW OR OTHERWISE, ARE HEREBY EXPRESSLY EXCLUDED.
ARTICLE 11
INDEMNIFICATION
11.1Indemnification by Licensor. Licensor will, at its sole expense, defend, indemnify, and hold harmless Licensee and its Affiliates and their respective officers, directors, shareholders or owners, employees, and agents (the “Licensee Indemnitees”) from and against any and all Third Party claims, suits, proceedings, damages, losses, liabilities, taxes, costs, expenses (including court costs and reasonable attorneys’ fees and expenses) and recoveries (collectively, “Claims”) to the extent that such Claims arise out of, are based on, or result from (a) the Exploitation of any Compound or Product by or on behalf of Licensor or its Affiliates or its or their subcontractors (for clarity, other than Licensee, its Affiliates or Sublicensees), (b) the breach of any of Licensor’s obligations under this Agreement, including Licensor’s 
27

representations and warranties, covenants and agreements, or (c) the willful misconduct or gross negligent acts of Licensor, its Affiliates, or the officers, directors, employees, or agents of Licensor or its Affiliates. The foregoing indemnity obligation will not apply (i) to the extent that the Licensee Indemnitees fail to comply with the indemnification procedures set forth in Section 11.3 and Licensor’s defense of the relevant Claims is prejudiced by such failure; or (ii) to Claims for which Licensee has an obligation to indemnify Licensor pursuant to Section 11.2, as to which Claims each Party will indemnify the other to the extent of its respective liability for such Claims.
11.2Indemnification by Licensee. Licensee will, at its sole expense, defend, indemnify, and hold harmless Licensor and its Affiliates and their respective officers, directors, shareholders or owners, employees, and agents (the “Licensor Indemnitees”) from and against any and all Third Party Claims to the extent that such Claims arise out of, are based on, or result from (a) the Exploitation of any Compound or Product by or on behalf of Licensee or its Affiliates or its or their Sublicensees, (b) the breach of any of Licensee’s obligations under this Agreement, including Licensee’s representations and warranties, covenants and agreements or (c) the willful misconduct or gross negligent acts of Licensee, its Affiliates, or the officers, directors, employees, or agents of Licensee or its Affiliates. The foregoing indemnity obligation will not apply (i) to the extent that the Licensor Indemnitees fail to comply with the indemnification procedures set forth in Section 11.3 and Licensee’s defense of the relevant Claims is prejudiced by such failure; or (ii) to Claims for which Licensor has an obligation to indemnify Licensee pursuant to Section 11.1, as to which Claims each Party will indemnify the other to the extent of its respective liability for such Claims.
11.3Indemnification Procedures. The Party claiming indemnity under this ARTICLE 11 (the “Indemnified Party”) will give written notice to the Party from whom indemnity is being sought (the “Indemnifying Party”) promptly after learning of a Claim. The Indemnified Party will provide the Indemnifying Party with reasonable assistance, at the Indemnifying Party’s expense, in connection with the defense of the Claim for which indemnity is being sought. The Indemnified Party may participate in and monitor such defense with counsel of its own choosing at its sole expense; provided, however, the Indemnifying Party may assume and conduct the defense of the Claim with counsel of its choice. The Indemnifying Party will not settle any Claim without the prior written consent of the Indemnified Party, not to be unreasonably withheld, unless the settlement involves only the payment of money. So long as the Indemnifying Party is actively defending the Claim in good faith, the Indemnified Party will not settle or compromise any such Claim without the prior written consent of the Indemnifying Party. If the Indemnifying Party does not assume and conduct the defense of the Claim as provided above, (a) the Indemnified Party may defend against, consent to the entry of any judgment, or enter into any settlement with respect to such Claim in any manner the Indemnified Party may deem reasonably appropriate (and the Indemnified Party need not consult with, or obtain any consent from, the Indemnifying Party in connection therewith), and (b) the Indemnifying Party will remain responsible to indemnify the Indemnified Party as provided in this ARTICLE 11.
11.4Limitation of Liability. EXCEPT (A) IN THE EVENT OF THE FRAUD OF A PARTY OR OF A PARTY’S BREACH OF ITS OBLIGATIONS UNDER ARTICLE 12, (B) TO THE EXTENT ANY SUCH DAMAGES ARE REQUIRED TO BE PAID TO A THIRD PARTY AS PART OF A CLAIM FOR WHICH A PARTY PROVIDES INDEMNIFICATION UNDER THIS ARTICLE 11 OR (C) IN CONNECTION WITH ANY MISREPRESENTATION, BREACH OR INACCURACY OF ANY REPRESENTATION MADE BY A PARTY, NEITHER PARTY NOR ANY OF ITS AFFILIATES OR SUBLICENSEES SHALL BE LIABLE IN CONTRACT, TORT, NEGLIGENCE, BREACH OF STATUTORY DUTY OR OTHERWISE FOR ANY INDIRECT, INCIDENTAL, CONSEQUENTIAL, SPECIAL, PUNITIVE, REMOTE, EXEMPLARY OR SPECULATIVE DAMAGES, INCLUDING BUT NOT LIMITED TO LOST PROFITS, ARISING FROM OR 
28

RELATING TO ANY BREACH OF THIS AGREEMENT, REGARDLESS OF ANY NOTICE OF THE POSSIBILITY OF SUCH DAMAGES OR THE FAILURE OF THE ESSENTIAL PURPOSE OF ANY REMEDY.
11.5Insurance. Licensee, [***], shall maintain clinical trials and product liability insurance in an amount consistent with industry standards for a company of similar standing during the term of this Agreement.  
ARTICLE 12
CONFIDENTIALITY
12.1Confidentiality. Each Party agrees that, during the Term and, subject to Section 12.5, for a period of [***] years thereafter, it and its Affiliates will keep confidential and will not publish or otherwise disclose and will not use for any purpose other than as provided for in this Agreement (which includes the exercise of any rights or the performance of any obligations hereunder or thereunder) any Confidential Information furnished to it or its Affiliate by or on behalf of the other Party or its Affiliate pursuant to this Agreement, except to the extent expressly authorized by this Agreement or as otherwise agreed to in writing by the Parties. The terms of the Agreement shall be Confidential Information of both Parties, and during the Term, Licensed Know-How shall be deemed Confidential Information of Licensee. The confidentiality and non-use obligations set forth in this Section 12.1 do not apply to any portion of the other Party’s Confidential Information that the receiving Party can demonstrate by competent written proof:
(a)was already known to the receiving Party or its Affiliate, other than under an obligation of confidentiality, at the time of disclosure by the other Party or its Affiliate;
(b)was generally available to the public or otherwise part of the public domain at the time of its disclosure to the receiving Party or its Affiliate;
(c)became generally available to the public or otherwise part of the public domain after its disclosure and other than through any act or omission of the receiving Party or its Affiliate in breach of this Agreement;
(d)was disclosed to the receiving Party or its Affiliate by a Third Party who had a legal right to make such disclosure and who did not obtain such information directly or indirectly from the other Party or its Affiliate; or
(e)was independently discovered or developed by the receiving Party or its Affiliate without access to or aid, application or use of the other Party’s Confidential Information, as evidenced by a contemporaneous writing.
12.2Authorized Disclosure. Notwithstanding the obligations set forth in Section 12.1, a Party or its Affiliate may disclose the other Party’s Confidential Information and the terms of this Agreement to the extent:
(a)such disclosure is reasonably necessary (i) for the filing or prosecuting of Patent rights as contemplated by this Agreement; (ii) to comply with the requirements of Regulatory Authorities and applicable Laws with respect to obtaining and maintaining Regulatory Approval(s) of Product; or (iii) for prosecuting or defending litigation or taking other appropriate enforcement actions as contemplated by this Agreement;
29

(b)such disclosure is reasonably necessary to its officers, directors, employees, agents, consultants, contractors, licensees, sublicensees, attorneys, accountants, advisors, lenders, insurers or licensors on a need-to-know basis for the sole purpose of performing its obligations or exercising its rights under this Agreement; provided that in each case, the disclosees are bound by obligations of confidentiality and non-use no less stringent than those contained in this Agreement;
(c)such disclosure is reasonably necessary to any bona fide potential or actual investor, acquiror, merger partner, Sublicensee or other financial or commercial partner for the sole purpose of evaluating an actual or potential investment, acquisition or other business relationship; provided that in each case, the disclosees are bound by reasonable written obligations of confidentiality and non-use; or
(d)such disclosure is reasonably necessary to comply with Laws, including regulations promulgated by applicable securities exchanges, court orders, administrative subpoenas or other orders by a Governmental Authority.
Notwithstanding the foregoing, if a Party or its Affiliate is required to make a disclosure of the other Party’s Confidential Information pursuant to Section 12.2(a) or 12.2(d), such Party will promptly notify in writing the other Party of such required disclosure and, upon the other Party’s request, such Party and its Affiliates will use reasonable and timely efforts to obtain, or to assist the other Party in obtaining, a protective order preventing or limiting the required disclosure.
12.3Publications. Licensee and its Affiliates shall be free to publish and present, and to authorize its Sublicensees to publish and present, the results of any preclinical study or Clinical Study or other Development activities with respect to a Compound or Product conducted by or on behalf of Licensee or its Affiliates or Sublicensees, [***]. Licensor shall not publish or present any Licensor Know-How without [***].
12.4Publicity; Terms of Agreement.
(a)The Parties agree that the material terms of this Agreement are the Confidential Information of both Parties, subject to the special authorized disclosure provisions set forth in this Section 12.4.
(b)The Parties will each (or jointly) make a public announcement of the execution of this Agreement, to be issued as a press release(s) drafted in a mutually agreed form which will be issued within four (4) Business Days after the Effective Date, as further agreed by the Parties, in their respective countries of incorporation. In addition, Licensee will file a Current Report on Form 8-K with the SEC.
(c)After release of such press release and filing of Licensee’s Current Report on Form 8-K, if either Party or its Affiliate desires to make a public announcement concerning the material terms of this Agreement, such Party will give reasonable prior advance written notice of the proposed text of such announcement to the other Party for its prior review and approval (except as otherwise provided), such approval not to be unreasonably withheld. A Party commenting on such a proposed announcement will provide its comments, if any, within [***] Business Days after receiving the announcement for review, or such shorter period as may be reasonably required in order for the proposing Party to comply with any applicable deadline for making such announcement (as such deadline is communicated by the proposing Party to the commenting Party). In addition, where required by Laws, including regulations promulgated by applicable securities exchanges, such Party or its Affiliate may make a press release (or SEC or other regulatory filing) announcing the achievement of each milestone under this Agreement as it is achieved, the achievements of Regulatory Approvals in the Territory as they occur, or any 
30

other material event with respect to this Agreement or the Parties’ performance thereof, subject only to the review procedure set forth in the preceding sentence; provided that the review period will be reduced to [***] Business Days (or such shorter period as may be reasonably required in order for the proposing Party to comply with any applicable legal deadline for making such press release (or SEC or other regulatory filing), as such deadline is communicated by the proposing Party to the commenting Party) if the deadline for making such disclosure is [***] Business Days after such achievement or event. In relation to the other Party’s review of such an announcement, such other Party may make specific, reasonable comments on such proposed press release (or SEC or other regulatory filing) within the prescribed time for commentary, but will not withhold, condition, or delay its consent to disclosure of the information that the relevant milestone or Regulatory Approval has been achieved or material event has occurred. Neither Party nor their Affiliates are required to seek the permission of the other Party to repeat or summarize any information regarding the terms of this Agreement that has already been substantially publicly disclosed by such Party or its Affiliate, or by the other Party or its Affiliate, in accordance with this Section 12.4, if such information remains accurate as of such time. Notwithstanding the foregoing, [***].
(d)The Parties acknowledge that either or both Parties may be obligated to file under Laws a copy of this Agreement with the U.S. Securities and Exchange Commission (“SEC”) or other Governmental Authorities. Each Party will make such a required filing and will request confidential treatment of the commercial terms and sensitive technical or other competitively sensitive terms hereof and thereof to the extent such confidential treatment is reasonably available to such Party. In the event of any such filing, each Party will provide the other Party with a copy of this Agreement marked to show the provisions for which such Party intends to seek confidential treatment and will reasonably consider and incorporate the other Party’s comments thereon to the extent consistent with the legal requirements, with respect to the filing Party, governing disclosure of material agreements and material information that must be publicly filed. The reviewing Party shall respond with any comments hereunder within [***] Business Days of receipt, unless a shorter deadline is required for the disclosing Party to comply with applicable reporting Laws.
12.5Return of Confidential Information. Except as otherwise set forth in this Agreement, upon termination of this Agreement, the receiving Party will promptly return all of the disclosing Party’s Confidential Information, including all reproductions and copies thereof in any medium, except that the receiving Party may retain a reasonable number of archival copies as may be required by law, its standard document retention policies, or to demonstrate its compliance with this Agreement.
12.6Unauthorized Use. If either Party becomes aware or has knowledge of any unauthorized use or disclosure of the other Party’s Confidential Information, it will promptly notify the other Party in writing of such unauthorized use or disclosure.
ARTICLE 13
TERM AND TERMINATION 
13.1Term. This Agreement becomes effective on the Effective Date, and, unless sooner terminated as specifically provided in this Agreement, continues in effect on a Product-by-Product and country-by-country basis until the expiration of the last Royalty Term for any Product in any country in the Territory (the “Term”). 
31

13.2Unilateral Termination by Licensee. 
(a)Termination Upon Written Notice. Notwithstanding any other provision of this Agreement, Licensee may at any time terminate this Agreement in its sole discretion, on a country-by-country basis, a Program-by-Program basis, or in its entirety, upon [***] days’ prior written notice to Licensor.
(b)Effect of Termination. Upon termination of this Agreement pursuant to [***], (i) all rights and the licenses granted to Licensee by Licensor with respect to [***] shall immediately terminate and, subject to this Section 13.2(b), all future obligations of each Party and its Affiliates under this Agreement with respect to [***] will immediately cease, (ii) Licensee will [***] with respect to [***], and (iii) at Licensor’s request, Licensee shall negotiate in good faith with Licensor commercially reasonable terms (including financial terms) upon which Licensee would grant to Licensor appropriate licenses under any Licensee Technology Controlled by Licensee or its Affiliates and assign to Licensor any Regulatory Materials or Regulatory Approval owned by Licensee or its Affiliates for purposes of Exploiting any Compound(s) or Product(s) in [***].
13.3Termination for Breach. 
(a)Default Notice. Each Party (the “Non-Breaching Party”) may terminate this Agreement, on a country-by-country basis, a Program-by-Program basis, or in its entirety, immediately upon written notice to the other Party (the “Breaching Party”) if the Breaching Party materially breaches its obligations under this Agreement and, after receiving written notice identifying such material breach in reasonable detail (a “Default Notice”), fails to cure such material breach within [***] days after delivery of the Default Notice (or within [***] days after delivery of the Default Notice if such material breach is solely based on the Breaching Party’s failure to pay any amounts due hereunder), provided that if a material breach (other than for non-payment) cannot reasonably be cured within such [***]-day period and the Breaching Party promptly delivers a plan to cure such material breach and uses commercially reasonable efforts to implement such plan, then the cure period shall be extended for a maximum cure period of [***] days from the date of the Default Notice. If the Breaching Party disputes in good faith the basis for termination and, on or before the end of the cure period, either Party has referred the matter to arbitration pursuant to Section 14.1, then the cure period will be tolled and this Agreement will not terminate unless and until the chief executive officer of Licensor and the chief executive officer of Licensee resolve the dispute or the arbitrators issue a final, binding, nonappealable ruling or award upholding such basis for termination (or unless and until the Breaching Party is no longer disputing such basis in good faith, if earlier). If the arbitrators issue a final, binding, nonappealable ruling or award upholding such basis for termination, then the cure period will resume, and the Breaching Party will have the remainder of the cure period to cure the material breach. If the material breach is so cured within the remainder of the cure period, then this Agreement will remain in full force and effect; otherwise, this Agreement will terminate as specified in the Default Notice. If the arbitrators issue a final binding nonappealable ruling rejecting such basis for termination, then this Agreement will remain in full force and effect. Notwithstanding the foregoing, if Licensee is the Breaching Party and the material breach is with respect to only one Program or a particular country, then this Agreement may be terminated only with respect to such Program or such country, and not in its entirety.
(b)Effect of Termination by Licensee. Upon termination by Licensee pursuant to [***], (i) all rights and the licenses granted to Licensee by Licensor with respect to [***] shall immediately terminate and, subject to this Section 13.3(b), all future obligations of each Party and its Affiliates with respect to [***] will immediately cease, (ii) Licensee will [***], and (iii) at Licensor’s request, Licensee shall negotiate in good faith with Licensor commercially reasonable terms (including financial terms) upon which Licensee would grant to 
32

Licensor appropriate licenses under any Licensee Technology Controlled by Licensee or its Affiliates and assign to Licensor any Regulatory Materials or Regulatory Approval owned by Licensee or its Affiliates for purposes of Exploiting any Compound(s) or Product(s) in [***].
(c)Effect of Termination by Licensor. Upon termination by Licensor pursuant to [***], (i) all rights and the licenses granted to Licensee by Licensor with respect to [***] shall immediately terminate and, subject to this Section 13.3(c), all future obligations of each Party and its Affiliates under this Agreement with respect to [***] will immediately cease, (ii) Licensee will [***], and (iii) Licensee shall (x) grant to Licensor a non-exclusive (which license may become exclusive upon agreement by the Parties in good faith on commercially reasonable terms, including financial terms), royalty-free, perpetual, and sublicensable license under any Licensee Technology owned by Licensee or its Affiliates to the extent necessary for Exploiting any Compound(s) or Product(s) in [***] and (y) assign to Licensor any relevant Regulatory Materials or Regulatory Approval owned by Licensee or its Affiliates with respect thereto.
(d)Survival of Certain Sublicenses. Upon termination of this Agreement by Licensor pursuant to Section 13.3(a), upon Licensee’s request, any sublicense granted by Licensee shall survive and shall automatically be assigned by Licensee to Licensor such that such sublicense becomes a direct license between Licensor and the applicable Sublicensee on the same terms and conditions as those set forth in this Agreement, to the extent applicable to the rights granted by Licensee to such Sublicensee, provided that such sublicense was granted in accordance with the terms of Section 2.1(b) and that such Sublicensee is in compliance with the terms of the sublicense agreement and agrees to comply with all applicable terms of this Agreement.
13.4Insolvency. Each Party shall have the right to terminate this Agreement upon written notice to the other Party: (a) if the other Party is declared insolvent or bankrupt by a court of competent jurisdiction; (b) if a voluntary or involuntary petition in bankruptcy is filed in any court of competent jurisdiction against the other Party and such petition is not dismissed within [***] days after filing; (c) if the other Party shall make or execute an assignment of substantially all of its assets for the benefit of creditors; or (d) substantially all of the assets of the other Party are seized or attached and not released within [***] days thereafter. In any event when one Party first becomes aware of the likely occurrence of any insolvency or bankruptcy event in regard to itself, it shall promptly so notify the other Party in writing in sufficient time to give the other Party sufficient notice to protect that Party’s interests under this Agreement. 
13.5Alternative to Termination. In the event that Licensee is entitled to terminate this Agreement (in whole or in part, as applicable) pursuant to Section 13.3(a), Licensee may, upon written notice to Licensor, elect to retain the rights and licenses granted by Licensor to Licensee hereunder, with all payments obligations of Licensee under ARTICLE 8 with respect to [***] reduced by [***] after delivery of such notice. For clarity, such election by Licensee shall not release Licensor from its obligation to continue to use reasonable effort to cure the applicable material breach or limit the right of Licensee to terminate this Agreement (in whole or in part, as applicable) if such material breach is not cured. 
13.6Survival. Termination or expiration of this Agreement will not affect rights or obligations of the Parties under this Agreement that have accrued before the date of termination or expiration. Notwithstanding anything to the contrary, the following provisions will survive any expiration or termination of this Agreement: ARTICLE 1 (Definitions), Section 5.2, last sentence in Section 8.3(b) (Royalty Term) Section 8.7 (Records), Section 8.8 (Audits), Section 8.9 (Taxes), Section 9.1 (Ownership of Inventions), Section 13.2(b) (Effect of Termination), Sections 13.3(b) (Effect of Termination by Licensee), 13.3(c) (Effect of Termination by Licensor), 13.3(d) (Survival of Certain Sublicenses), and this Section 13.6 (Survival), ARTICLE 
33

11 (Indemnification), ARTICLE 12 (Confidentiality), ARTICLE 14 (Dispute Resolution), and ARTICLE 15 (Miscellaneous). 
ARTICLE 14
DISPUTE RESOLUTION
14.1Arbitration. In the event of any disputes, controversies or differences between the Parties arising out of, in relation to, or in connection with this Agreement, including any alleged failure to perform, or breach, of this Agreement, or any issue relating to the validity, construction, interpretation, enforceability, breach, performance, application, or termination of this Agreement (“Dispute”), then upon the written request of either Party, the Parties agree to meet and discuss in good faith an amicable resolution thereof, which good faith efforts include at least one (1) meeting between the most senior executive officer of Licensor and the chief executive officer of Licensee. If the Dispute is not resolved within [***] days following the written request for amicable resolution, then either Party may initiate arbitration under this Section 14.1. Any Dispute that the Parties do not resolve through amicable resolution will be settled by final, binding and conclusive arbitration administered by JAMS, Inc., the alternative dispute resolution company formerly known as Judicial Arbitration and Mediation Services, Inc., pursuant to its Comprehensive Arbitration Rules and Procedures then in effect (the “JAMS Rules”), except as otherwise provided. The number of the arbitrators will be three, with each Party selecting one arbitrator and those two arbitrators selected by the Parties then selecting the third arbitrator. The arbitration will be conducted in New York, New York, U.S. The language of the arbitration will be in English. Judgment on the award may be entered in any court having jurisdiction and the Parties may file in a court of appropriate jurisdiction to enforce an arbitral award issued hereunder. Except as may be required by applicable Laws, neither Party may disclose the existence, content, or results of any arbitration hereunder without the prior written consent of both Parties. 
14.2Equitable Relief. Notwithstanding Section 14.1, each Party acknowledges that its breach of ARTICLE 12 may cause irreparable harm to the other Party, which cannot be reasonably or adequately compensated by damages in an action at law. By reason thereof, each Party agrees that the other Party may, in addition to any other remedies it may have under this Agreement or otherwise, seek preliminary and permanent injunctive and other equitable relief from any state or federal court of competent jurisdiction in New York, New York, U.S. to prevent or curtail any actual or threatened breach of ARTICLE 12 that is reasonably likely to cause it irreparable harm. In addition, notwithstanding Section 14.1, to the fullest extent provided by Law, either Party may bring an action in any court of competent jurisdiction for injunctive relief (or any other provisional remedy) to protect a Party’s rights or enforce a Party’s obligations under this Agreement pending final resolution of any claims related thereto pursuant to the dispute resolution procedure set forth in Section 14.1. 
14.3Governing Law. This Agreement and all disputes arising out of or related to this Agreement or any breach hereof are governed by and construed under the Laws of the State of Delaware, U.S. without giving effect to any choice of law principles that would require the application of the Laws of a different state or country. 
14.4Patent and Trademark Disputes. Notwithstanding Section 14.1, any dispute, controversy or claim relating to the scope, validity, enforceability of any Patent or trademark rights hereunder will be submitted to a court of competent jurisdiction in the country in which such Patent or trademark rights were granted or arose.
34

ARTICLE 15
MISCELLANEOUS
15.1Entire Agreement; Amendment. This Agreement, including the Exhibits hereto, and any other documents delivered pursuant hereto or thereto, and any subsequent amendments of the same, set forth the complete, final, and exclusive agreement and all the covenants, promises, agreements, warranties, representations, conditions, and understandings between the Parties hereto and thereto and their Affiliates with respect to the subject matter hereof and supersede, as of the Effective Date, all prior and contemporaneous agreements and understandings between the Parties with respect to the subject matter hereof. There are no covenants, promises, agreements, warranties, representations, conditions, or understandings, either oral or written, between the Parties with respect to the subject matter of this Agreement other than as are set forth in this Agreement and the other documents referred to in the preceding sentence. No subsequent alteration, amendment, change, or addition to this Agreement will be binding upon the Parties unless reduced to writing and signed by an authorized officer of each Party.
15.2Force Majeure. Both Parties will be excused from the performance of their obligations under this Agreement to the extent that such performance is prevented by force majeure and the non-performing Party promptly provides written notice of the prevention to the other Party. Such excuse will continue for so long as the condition constituting force majeure continues and the non-performing Party takes reasonable efforts to remove the condition. For purposes of this Agreement, force majeure includes conditions beyond the reasonable control of the Parties, regardless of whether it could be anticipated or not, including an act of God, war, civil commotion, terrorist or criminal act, epidemic, pandemic, failure or default of public utilities or common carriers, destruction of production facilities or materials by fire, earthquake, and storm or like natural catastrophe, or as otherwise defined or allowed pursuant to Governing Law. Notwithstanding the foregoing, a Party will not be excused from making payments owed hereunder because of a force majeure affecting such Party. If a force majeure persists for more than [***] days, then the Parties will discuss in good faith the modification of the Parties’ obligations under this Agreement to mitigate the delays caused by such force majeure.
15.3Notices. Any notice required or permitted to be given under this Agreement will be in writing, will specifically refer to this Agreement, and will be addressed to the appropriate Party at the address specified below or such other address as may be specified by such Party in writing in accordance with this Section 15.3, and will be deemed to have been given for all purposes (a) when received, if hand-delivered or sent by email with non-automated confirmed read receipt or a reputable courier service, or (b) [***] Business Days after mailing, if mailed by first class certified or registered airmail, postage prepaid, return receipt requested.
						
	If to Licensor:	Carna Biosciences, Inc. 
		BMA 3F, 1-5-5, Minatojima-Minamimachi,
		Chuo-ku, Kobe, Hyogo, JAPAN

		Attn: [***]

		Email: [***]

		

35

With a copy to (which will not constitute notice):
						
		Carna Biosciences, Inc. 
		BMA 3F, 1-5-5, Minatojima-Minamimachi,

		Chuo-ku, Kobe, Hyogo, JAPAN 

		Attn: [***]

		Email: [***]

		

	If to Licensee:	Brickell Biotech, Inc.

		5777 Central Avenue

		Boulder, CO 80301

		Attn: [***]

		Email: [***]

		

With copies to (which will not constitute notice):
						
		Brickell Biotech, Inc.

		5777 Central Avenue

		Boulder, CO  80301

		Attn:  [***]

		Email:  [***]
		

15.4No Strict Construction; Interpretation; Headings. The language in this Agreement is to be construed in all cases according to its fair and reasonable meaning to effect the purpose of the Agreement. Except where the context otherwise requires, wherever used, the singular includes the plural, the plural the singular, the use of any gender applies to all genders. The word “or” is used in the disjunctive sense and the word “and” is used in the conjunctive sense. The captions of this Agreement are for convenience of reference only and in no way define, describe, extend, or limit the scope or intent of this Agreement or the intent of any provision contained in this Agreement. The term “including,” “include,” or “includes”, whether or not followed by “without limitation” or “including, but not limited to,” or words of similar import, shall be construed to mean in each case including, without limiting the generality of any description preceding such term. The Parties agree that no meaning should be inferred about the use of “without limitation” or “including, but not limited to” in some instances but not others. Unless the context requires otherwise, (i) any definition of or reference to any agreement, instrument or other document will be construed as referring to such agreement, instrument or other document as from time to time amended, supplemented or otherwise modified (subject to any restrictions on such amendments, supplements or modifications set forth herein or therein), (ii) any reference to any Laws will be construed as referring to such Laws as from time to time enacted, repealed or amended, (iii) any reference to any person will be construed to include the person’s successors and permitted assigns, (iv) the words “herein”, “hereof” and “hereunder”, and words of similar import, will be construed to refer to this Agreement in its entirety and not to any particular provision hereof, (v) any reference to the words “mutually agree” or “mutual written agreement” will not impose any obligation on either Party to agree to any terms relating thereto or to engage in discussions relating to such terms except as such Party may determine in such Party’s sole discretion, (vi) all references to Sections, Exhibits or Schedules will be construed to refer to Sections, Exhibits and Schedules to this Agreement, (vii) the word “days” means calendar days 
36

unless otherwise specified, and (viii) the words “copy” and “copies” and words of similar import when used in this Agreement include, to the extent available, electronic copies, files or databases containing the information, files, items, documents or materials to which such words apply. The headings of each Article and Section in this Agreement have been inserted for convenience of reference only and are not intended to limit or expand on the meaning of the language contained in the particular Article or Section. Each Party represents that it has been represented by legal counsel in connection with this Agreement and acknowledges that it has participated in the drafting hereof. In interpreting and applying the terms and provisions of this Agreement, the Parties agree that no presumption will apply against the Party which drafted such terms and provisions.
15.5Assignment. Neither Party may assign or transfer this Agreement or any rights or obligations hereunder without the prior written consent of the other Party, except that a Party may make such an assignment without the other Party’s consent to its Affiliates or to a Third Party successor or transferee to all or substantially all of the assets of such Party to which this Agreement relates (such Third Party, an “Acquiror”), whether in a merger, sale of stock, sale of assets or other transaction. Any successor or assignee of rights or obligations permitted hereunder will, in writing to the other Party, expressly assume performance of such rights or obligations; provided that in the case of an assignment to an Affiliate, the assigning Party shall remain primarily liable for performance under this Agreement. Any permitted assignment will be binding on the successors of the assigning Party. Any assignment or attempted assignment by either Party in violation of the terms of this Section 15.5 is null, void and of no legal effect.
15.6Performance by Affiliates. Each Party may discharge any obligations and exercise any right hereunder through any of its Affiliates. Each Party hereby guarantees the performance by its Affiliates of such Party’s obligations under this Agreement and will cause its Affiliates to comply with the provisions of this Agreement in connection with such performance. Any breach by a Party’s Affiliate of any of such Party’s obligations under this Agreement is a breach by such Party, and the other Party may proceed directly against such Party without any obligation to first proceed against such Party’s Affiliate.
15.7Further Assurances and Actions. Each Party, upon the request of the other Party, whether before or after the Effective Date and without further consideration, will do, execute, acknowledge, and deliver or cause to be done, executed, acknowledged or delivered all such further acts, deeds, documents, assignments, transfers, conveyances, powers of attorney, instruments and assurances as may be reasonably necessary to effect complete consummation of the transactions contemplated by this Agreement, and to do all such other acts, as may be necessary or appropriate to carry out the purposes and intent of this Agreement. The Parties agree to execute and deliver such other documents, certificates, agreements and other writings in a timely manner and to take such other actions as may be reasonably necessary to consummate or implement expeditiously the transactions contemplated by this Agreement.
15.8Severability. Each of the provisions contained in this Agreement will be severable, and the unenforceability of one will not affect the enforceability of any others or of the remainder of this Agreement. If any one or more of the provisions of this Agreement, or the application thereof in any circumstances, is held to be invalid, illegal, or unenforceable in any respect for any reason, the Parties will negotiate in good faith with a view to the substitution therefor of a suitable and equitable solution to carry out, so far as may be valid and enforceable, the intent and purpose of such invalid provision; provided, however, that the validity, legality and enforceability of any such provision in every other respect and of the remaining provisions of this Agreement will not be in any way impaired thereby, it being intended that all of the rights and privileges of the Parties hereto will be enforceable to the fullest extent permitted by Law.
37

15.9No Waiver. Any term or condition of this Agreement may be waived at any time by the Party that is entitled to the benefit thereof, but no such waiver will be effective unless set forth in a written instrument duly executed by or on behalf of the Party waiving such term or condition. The waiver, delay or the failure of any Party to enforce or exercise any term, condition or part of this Agreement at any time or in any one or more instances will not be deemed to be or construed as a waiver of the same or any other term, condition or part, nor will it forfeit any rights, power or privilege to future enforcement thereof. No single or partial exercise of any right, power or privilege will preclude any other or further exercise of such right, power or privilege or the exercise of any other right, power or privilege. No waiver that may be given by a Party will be applicable except in the specific instance for which it is given. Except as expressly set forth in this Agreement, all rights and remedies available to a Party, whether under this Agreement or afforded by Law or otherwise, will be cumulative and not in the alternative to any other rights or remedies that may be available to such Party.
15.10Relationship of the Parties. Neither Party will have any responsibility for the hiring, termination or compensation of the other Party’s employees or for any employee benefits of such employee. No employee or representative of a Party will have any authority to bind or obligate the other Party to this Agreement for any sum or in any manner whatsoever, or to create or impose any contractual or other liability on the other Party without said Party’s written approval. For all purposes, and notwithstanding any other provision of this Agreement to the contrary, Licensor’s legal relationship to Licensee under this Agreement will be that of independent contractor and nothing in this Agreement gives either Party the power or authority to act for, bind, or commit the other Party in any way. This Agreement is not a partnership agreement. Nothing in this Agreement will be construed to establish a relationship of partners, principal and agent or joint venturers between the Parties or their respective employees, Affiliates or sublicensees. Nothing contained in this Agreement shall be construed to create a “separate entity” or “business entity” within the meaning of the U.S. Internal Revenue Code or the regulations thereunder and any foreign equivalents thereto. Neither Licensee nor Licensor will make any statements, representations, or commitments of any kind, or to take any action that is binding on the other, without the prior written consent of the other Party to do so.
15.11English Language. This Agreement was prepared in the English language, which language governs the interpretation of, and any dispute regarding, the terms of this Agreement.
15.12Counterparts. This Agreement may be executed in one or more counterparts, each of which is an original, but all of which together constitute one and the same instrument. 
15.13Schedules and Exhibits. The disclosure of any matter in any Section of or on any Schedule or Exhibit to this Agreement will only be deemed to be a disclosure for the Section or subsection of this Agreement to which it corresponds in number, unless the applicability of such Schedule or Exhibit to any other Section is readily apparent. The disclosure of any matter in any Schedule or Exhibit to this Agreement will expressly not be deemed to (a) constitute an admission by either Party hereto, or (b) imply that any such matter is material for purposes of this Agreement.
15.14Expenses. Each of the Parties will bear its own direct and indirect expenses incurred in connection with the negotiation and preparation of this Agreement and, except as set forth in this Agreement, the performance of the obligations contemplated hereby and thereby.
15.15Section 365(n). The Parties acknowledge and agree that the licenses granted by the Parties pursuant to Article 2 and all other rights granted under or pursuant to this Agreement are, for purposes of Section 365(n), licenses of rights to “intellectual property” as defined under Section 101(35A) of the Bankruptcy Code (or analogous foreign provisions), and that this Agreement is an executory contract governed by Section 365(n) if a bankruptcy proceeding is 
38

commenced involving either Party (as licensor hereunder). Licensee, as the licensee of such rights under Article 2, retains and may fully exercise all of its rights and elections under the Bankruptcy Code. The foregoing provisions of this Section 15.15 are without prejudice to any rights the Parties may have arising under the Bankruptcy Code or other applicable Laws.
[Remainder of this page intentionally left blank]
39

IN WITNESS WHEREOF, the Parties hereto have caused this Agreement to be executed by their duly authorized officers as of the Effective Date.
						
	CARNA BIOSCIENCES, INC.

	BRICKELL BIOTECH, INC.
	By: /s/ [***]                                             
	By: /s/ Robert Brown                                 

	Name: [***]
	Name: Robert Brown
	Title: [***]
	Title:  Chief Executive Officer

SIGNATURE PAGE TO EXCLUSIVE LICENSE AGREEMENT

EXHIBIT A

LICENSOR PATENTS 

															
	Country	 	Application No.	 	Application Date
	[***]	 	[***]
	 	[***]
	[***]	 	[***]	 	[***]
	[***]	 	[***]	 	[***]

EXHIBIT B

CHEMICAL STRUCTURE OF [***]

[***]

EXHIBIT C
MATERIALS AND INFORMATION TO BE TRANSFERRED TO LICENSEE
[***]
							
	[***]				
					
					
					
					
					
					
					
					
					
					
					
					
					
					
					
					
					
					
					
					
					
					
					
					

[***]
[***]ex_330674.htm

 

Exhibit 10.1

 

Preferred Stock Purchase and Redemption Agreement

 

This Preferred Stock Purchase and Redemption Agreement (this “Agreement”) is entered into effective January 31, 2022 (the “Effective Date”) by NovAccess Global Inc., a Colorado corporation (“NovAccess”), TN3, LLC, a Wyoming limited liability company (“TN3”), Mr. Daniel G. Martin, individually (“Martin”), Irvin Consulting, LLC, a California limited liability company (“IC”), and Dr. Dwain Morris-Irvin, individually (“Irvin”).

 

Recitals

 

A.         TN3 is the sole owner of 25,000 shares of Series B Convertible Preferred Stock, $0.01 par value per share, of NovAccess (the “Shares”).

 

B.         Martin is the sole owner and manager of TN3.

 

C.         NovAccess desires to purchase and redeem 24,400 of the Shares (the “Redeemed Shares”), and TN3 desires to sell the Redeemed Shares to NovAccess.

 

D.         IC desires to purchase 600 of the Shares (the “Purchased Shares”), and TN3 desires to sell the Purchased Shares to IC.

 

E.         Irvin is the sole owner and president of IC.

 

NovAccess, TN3, Martin, IC and Irvin (together, the “Parties”) agree as follows:

 

1         Sale, Purchase and Redemption of Shares

 

1.1         Sale of Shares. On the Closing Date (as defined below), TN3 shall sell and transfer the Redeemed Shares to NovAccess free and clear of all liens, encumbrances, charges and assessments of every nature (“Encumbrance”), and the Redeemed Shares shall be redeemed, cancelled and no longer issued and outstanding. On the Closing Date, TN3 shall sell and transfer the Purchased Shares to IC free and clear of all Encumbrances, and IC shall accept and acquire the Purchased Shares.

 

1.2         Payment by NovAccess of Cash Purchase Price. The cash purchase price for the Shares shall be US $250,000 payable as provided for in this Section 1.2 (collectively, the “Purchase Price”). On January 20, 2022, NovAccess paid TN3 $12,500. On the Effective Date, NovAccess shall pay to TN3 $12,500 in immediately available funds (together with the January 20, 2022 payment, the “Down Payment”). On the first day of each month after the Closing Date, NovAccess shall pay to TN3 $25,000 in immediately available funds until the Purchase Price is paid in full. However, if NovAccess completes a third-party equity financing with gross cash proceeds to NovAccess of at least $2,500,000 in the aggregate, then NovAccess shall pay the remaining unpaid Purchase Price to TN3 within five days of NovAccess’ receipt of the financing proceeds.

 

 

 

 

1.3         Payment by NovAccess of Stock Purchase Price. On the Closing Date, NovAccess shall issue to TN3 1,502,670 unregistered shares of common stock, no par value (the “Common Stock”).

 

1.4         Payment by IC. On the Closing Date, IC will pay to NovAccess $7,223 in immediately available funds. This amount represents IC’s pro rata share (2.4%) of: (a) the Purchase Price; and (b) the closing price of the Common Stock on the OTC Pink Market the day before the Effective Date.

 

2         Representations of NovAccess

 

NovAccess represents to TN3 and Martin (all sections) and IC and Irvin (Sections 2.1, 2.2 and 2.5) as follows:

 

2.1         Authority; No Conflict. The board of directors of NovAccess has authorized the execution, delivery and performance of this Agreement by NovAccess. The execution of this Agreement and the consummation of the transactions contemplated by this Agreement will not result in the breach of any term or provision of, or constitute a default under, any organizational documents, agreement or instrument to which NovAccess or any of its subsidiaries is a party or to which it or any of its assets, operations or subsidiaries are subject.

 

2.2         Legal Proceedings. None of NovAccess or its affiliates is a party to any claim, action, suit, proceeding, or governmental investigation (“Action”), and, to NovAccess’ knowledge, there is no threatened Action, in either case: (a) relating to or affecting the Common Stock or in which a charging order against the Common Stock has been sought or awarded; or (b) that challenges or seeks to prevent, enjoin, or otherwise delay the transactions contemplated by this Agreement.

 

2.3         Common Stock. The Common Stock has been duly authorized, and when issued pursuant to the terms of this Agreement, will be validly issued, fully paid and non-assessable.

 

2.4         Solvency. After giving effect to the payment of the Purchase Price to TN3, the liabilities of NovAccess will not exceed the fair value of the assets of NovAccess.

 

2.5         No Additional Representations. Except for the representations expressly set forth in this Agreement, NovAccess acknowledges and agrees that none of the other Parties or their affiliates have made any other express or implied representation or warranty whatsoever in connection with this Agreement or the transactions contemplated by this Agreement.

 

3         Representations of TN3 and Martin

 

TN3 and Martin jointly and severally represent to NovAccess (all sections) and IC and Irvin (Sections 3.1 to 3.3 and 3.6) as follows:

 

3.1         The Shares. The Shares are free and clear of all Encumbrances and will be free and clear of all Encumbrances on the Closing Date. No person or entity has any right to acquire the Shares

 

2

 

 

and the preferred stock purchase agreement between GPC Holdings, Inc. and TN3 dated October 26, 2021 has been terminated and is no longer in effect. Other than the Shares, neither TN3 nor Martin is the beneficial owner of or has the right to acquire any equity securities of NovAccess.

 

3.2         Authority; No Conflict. The sole member and manager of TN3 has authorized the execution, delivery and performance of this Agreement by TN3. The execution of this Agreement and the consummation of the transactions contemplated by this Agreement will not result in the breach of any term or provision of, or constitute a default under, any organizational documents, agreement or instrument to which either TN3, Martin or their affiliates is a party or to which it or any of their assets, operations or subsidiaries are subject.

 

3.3         Legal Proceedings. None of TN3, Martin or their affiliates is a party to any Action, and, to TN3 and Martin’s knowledge, there is no threatened Action, in either case: (a) relating to or affecting the Shares or in which a charging order against the Shares has been sought or awarded; or (b) that challenges or seeks to prevent, enjoin, or otherwise delay the transactions contemplated by this Agreement.

 

3.4         Securities Matters. TN3 understands that the sale of the Common Stock is intended to be exempt from registration under Section 4(a)(2) of the Securities Act of 1933 (the “Securities Act”), and TN3 represents and warrants that TN3 has been advised that the Shares have not been registered under the Securities Act and, therefore, cannot be resold unless they are registered under the Securities Act or unless an exemption from registration is available. TN3 is an “accredited investor” as defined in Rule 501(a) under the Securities Act. TN3 agrees to abide by the Securities Act Rule 144(e) resale volume restrictions applicable to TN3 as a significant shareholder of NovAccess in connection with the re-sale of the Common Stock.

 

3.5         Tax Matters. Martin is not relying on NovAccess for tax advice concerning the sale and redemption of the Shares and will be responsible for all taxes of TN3 resulting from TN3’s receipt of the Purchase Price and Common Stock, including any transfer or similar taxes. Neither TN3 nor Martin is a foreign person as such term is used in Internal Revenue Code of 1986 Section 1446(f) or Treasury Regulations Section 1.1445-2.

 

3.6         No Additional Representations. Except for the representations expressly set forth in this Agreement, each of TN3 and Martin acknowledges and agrees that none of the other Parties or their affiliates have made any other express or implied representation or warranty whatsoever in connection with this Agreement or the transactions contemplated by this Agreement.

 

4         Representations of IC and Irvin

 

IC and Irvin jointly and severally represent to NovAccess, TN3 and Martin as follows:

 

4.1         Authority; No Conflict. The sole member of IC has authorized the execution, delivery and performance of this Agreement by IC. The execution of this Agreement and the consummation of the transactions contemplated by this Agreement will not result in the breach of any term or

 

3

 

 

provision of, or constitute a default under, any organizational documents, agreement or instrument to which either IC, Irvin or their affiliates is a party or to which it or any of their assets, operations or subsidiaries are subject.

 

4.2         Legal Proceedings. None of IC, Irvin or their affiliates is a party to any Action and, to IC and Irvin’s knowledge, there is no threatened Action, in either case, that challenges or seeks to prevent, enjoin, or otherwise delay the transactions contemplated by this Agreement.

 

4.3         Securities Matters. IC understands that the sale of the Purchased Shares is intended to be exempt from registration under Section 4(a)(1) of the Securities Act, and IC represents and warrants that IC has been advised that the Purchased Shares have not been registered under the Securities Act and, therefore, cannot be resold unless they are registered under the Securities Act or unless an exemption from registration is available. IC is an “accredited investor” as defined in Rule 501(a) under the Securities Act.

 

4.4         No Additional Representations. Except for the representations expressly set forth in this Agreement, each of IC and Irvin acknowledges and agrees that none of the other Parties or their affiliates have made any other express or implied representation or warranty whatsoever in connection with this Agreement or the transactions contemplated by this Agreement.

 

5         Additional Agreements of the Parties

 

5.1         Schedule 14F-1. As soon as possible after the Effective Date, NovAccess shall file with the Securities and Exchange Commission (the “SEC”) a Schedule 14F-1 to disclose the change in the board of directors of NovAccess and other transactions contemplated by this Agreement (the “Schedule 14F-1”), and Martin agrees to cooperate and assist NovAccess with the Schedule 14F-1 filing.

 

5.2         Management Agreement. NovAccess entered into a management services agreement with TN3 dated September 4, 2020 (as amended, the “Management Agreement”). NovAccess and TN3 agree that, effective the Closing Date, the Management Agreement shall be terminated and that all services to be provided by TN3 to NovAccess and all payments to be made by NovAccess to TN3 under the Management Agreement shall be considered satisfied by both NovAccess and TN3.

 

5.3         Board of Directors and Officers. At or prior to the Closing (as defined below), to be effective on the Closing Date: (a) the Parties shall execute all resolutions, resignations, appointments and other documents required to cause the board of directors of NovAccess to consist of Irvin and John Cassarini; and (b) Martin shall resign as chairman of NovAccess.

 

5.4         Innovest Dividend of NovAccess Shares. Innovest Global, Inc., a Nevada corporation (“Innovest”), owns 7,500,000 shares of NovAccess common stock, no par value (the “Innovest Shares”). NovAccess intends to register the Innovest Shares for resale under the Securities Act (the “Innovest Registration”) as soon as reasonably possible after the Closing Date to allow

 

4

 

 

Innovest to distribute the Innovest Shares to the shareholders of Innovest on a pro rata basis based on their holdings of common stock of Innovest (the “Innovest Distribution”). Martin agrees to obtain the written agreement of Innovest, in form and substance reasonably acceptable to NovAccess, to complete the Innovest Distribution after the Innovest Registration is effective (the “Innovest Agreement”).

 

5.5         Filing of Current Information. For eighteen months following the Closing Date, NovAccess agrees to: (a) make certain that “adequate current public information” concerning NovAccess and NovAccess’ common stock “is available” within the meaning of Rule 144(c)(2) under the Securities Act, including all of the information (collectively, the “Information”) that a broker-dealer would be required to obtain from NovAccess to publish a quotation for NovAccess’ common stock under Rule 15c2-11 under the Securities Exchange Act of 1934 (the “Exchange Act”); (b) timely file the Information with the SEC or the OTC Market; (c) comply on a timely basis with all filing requirements applicable to it pursuant to the Exchange Act; and (d) cause NovAccess’ common stock to be quoted on the OTC Market or listed on a national securities exchange such as the New York Stock Exchange.

 

5.6         D&O Insurance. NovAccess agrees to use its reasonable best efforts to: (a) as soon as possible following the Effective Date and prior to the Closing Date, obtain a policy of directors’ and officers’ liability insurance and fiduciary liability insurance covering NovAccess’ then current directors and officers, including Martin (the “D&O Insurance”); (b) and maintain the D&O Insurance for at least twelve months following the Closing Date.

 

5.7         Publicity and Announcements. No Party may publicly disclose (orally or in writing) or issue any press release regarding the existence or terms of this Agreement, or the transactions contemplated by this Agreement, without the prior written approval of the other Parties (which shall not be unreasonably withheld or delayed), except to the extent that NovAccess (based on the advice of counsel) is required to make any public disclosure or filing regarding the subject matter of this Agreement.

 

5.8         Legal Fees and Expenses. The Parties agree that all costs and expenses incurred in connection with this Agreement and the transactions contemplated by this Agreement shall be paid by the Party incurring such costs and expenses.

 

5.9         Further Actions. After the Effective Date, the Parties agree to take all actions reasonably necessary to effectuate the transactions contemplated by this Agreement.

 

6         Releases

 

6.1         By NovAccess. In consideration of the covenants and agreements of each of TN3 and Martin included in this Agreement, effective upon the Closing Date, NovAccess, on behalf of itself and each of its subsidiaries, directors, and officers, and any of its or their successors, assigns, and affiliates (other than TN3 or Martin) (collectively, the “NovAccess Releasing Parties”), hereby

 

5

 

 

absolutely, unconditionally, and irrevocably releases and discharges each of TN3 and Martin, and each of its members, managers, officers, agents, employees, and representatives, and any of its or their successors, assigns, and affiliates (collectively, the “Martin Released Parties”), from any and all claims, counterclaims, actions, causes of action, suits, defenses, debts, obligations, promises, expenses, liabilities, setoffs, accounts, covenants, contracts, agreements, costs, judgments, and demands whatsoever, whether at law, in equity, contract, tort, or otherwise (whether fixed or contingent, known or unknown, liquidated or unliquidated) (each, a “Claim”), including, without limitation, Claims arising under the Management Services Agreement, which any of the NovAccess Releasing Parties now has, or may hereafter have, against any of the Martin Released Parties, arising out of or relating to events, actions, omissions, facts, or circumstances occurring, arising, or existing at or prior to the Closing Date; provided, however, that the foregoing release shall not affect the rights and remedies of the NovAccess Releasing Parties under this Agreement, which rights and remedies of any NovAccess Releasing Party will continue in effect.

 

6.2         By Martin and TN3. In consideration of the covenants and agreements of NovAccess included in this Agreement, effective upon the Closing Date, each of Martin and TN3, on behalf of itself and each of its members, managers, officers, agents, employees, and representatives, and any of its or their successors, assigns, and affiliates (other than NovAccess) (collectively, the “Martin Releasing Parties”), hereby absolutely, unconditionally, and irrevocably releases and discharges NovAccess, and each of its shareholders, directors, officers, agents, employees, and representatives, and any of its or their successors, assigns, and affiliates (collectively, the “NovAccess Released Parties”), from any and all Claims, including, without limitation, Claims arising under the Management Services Agreement, which any of the Martin Releasing Parties now has, or may hereafter have, against any of the NovAccess Released Parties, arising out of or relating to events, actions, omissions, facts, or circumstances occurring, arising, or existing at or prior to the Closing Date; provided, however, that the foregoing release shall not affect the rights and remedies of the Martin Releasing Parties under (a) NovAccess’ articles of incorporation or by-laws; (b) the D&O Insurance of other insurance policies of NovAccess; or (c) this Agreement, each of which rights and remedies of any Martin Releasing Party will continue in effect.

 

7         Indemnification

 

7.1          By NovAccess. NovAccess agrees to indemnify, defend and hold harmless TN3, Martin, IC and Irvin against any and all claims, demands, losses, costs, expenses, obligations, liabilities and damages, including interest, penalties and reasonable attorneys’ fees and costs (“Losses”) incurred by TN3, Martin, IC or Irvin, arising, resulting from or relating to any breach of, or failure or failure to perform, by NovAccess of any of its representations, warranties, covenants or agreements in this Agreement.

 

6

 

 

7.2         By TN3 and Martin. Each of TN3 and Martin agrees to indemnify, defend and hold harmless NovAccess, IC and Irvin against any and all Losses incurred by NovAccess, IC or Irvin arising, resulting from or relating to any breach of, or failure or failure to perform, by TN3 or Martin of any of its or his representations, warranties, covenants or agreements in this Agreement.

 

7.3         By IC and Irvin. Each of IC and Irvin agrees to indemnify, defend and hold harmless NovAccess, TN3 and Martin against any and all Losses incurred by NovAccess, TN3 or Martin arising, resulting from or relating to any breach of, or failure or failure to perform, by IC or Irvin of any of its or his representations, warranties, covenants or agreements in this Agreement.

 

8         Closing

 

8.1         The Closing. The closing of the sale of the Redeemed Shares from TN3 to NovAccess and the Purchased Shares from TN3 to IC (the “Closing”) will occur on the date agreed to by NovAccess and TN3, but in no event more than five business days after the closing conditions specified in Section 8.2 below have been satisfied or waived (the “Closing Date”). The Closing will be conducted remotely, by email, phone and wire transfer of immediately available funds.

 

8.2         Closing Conditions. The obligation of each Party to effect the Closing is subject to the satisfaction or waiver at or prior to the Closing of the following conditions: (a) NovAccess has mailed the Schedule 14F-1 to its shareholders of record and the ten-day waiting period under Rule 14f-1 of the Exchange Act has expired; (b) no law, rule, judgment or order, whether preliminary, temporary or permanent, will be in effect that prevents, makes illegal or prohibits the consummation of the Closing; (c) the representations of each of the other Parties contained in this Agreement will be true and correct at and as of the Effective Date and at and as of the Closing Date as if made at and as of the Closing Date; and (d) each other Party will have performed in all material respects all covenants and agreements required to be performed by them under this Agreement at or prior to the Closing. In addition, the obligation of NovAccess to effect the Closing is subject to Martin delivering the executed Innovest Agreement to NovAccess.

 

8.3         Termination Rights. NovAccess and Martin may terminate this Agreement at any time prior to the Closing Date, by mutual written consent. Each of NovAccess and Martin may terminate this Agreement, at any time prior to the Closing Date, if the Closing has not occurred by 5:00 P.M. Cleveland time on March 31, 2022 (the “End Date”); provided, however, that neither NovAccess nor Martin may terminate this Agreement if it or he (and, in the case of Martin, TN3) is in breach of any of its or his covenants or agreements and such breach has caused or resulted in either: (a) the failure to satisfy the conditions to the obligations of the terminating Party to consummate the Closing prior to the End Date; or (b) the failure of the Closing to have occurred prior to the End Date. If NovAccess terminates this Agreement pursuant to the previous sentence (a) as a result of either TN3 or Martin’s failure or refusal to consummate the Closing; or (b) either TN3 or Martin is in breach of any of its or his covenants or agreements contained in this

 

7

 

 

Agreement at the time of NovAccess’ termination, then TN3 agrees to return the Down Payment to NovAccess within five days of NovAccess’ termination of this Agreement.

 

9         Miscellaneous

 

9.1         Notices. All notices and other communications under this Agreement must be in writing and will be deemed given when sent by email (with electronic confirmation of transmission) to the following email addresses (or to another email address that a Party may have specified by notice given to the other Parties pursuant to this provision): (a) to NovAccess to Neil J. Laird at Neil@NovaccessGlobal.com, with a copy to Christopher J. Hubbert at CJH@KJK.com; (b) to TN3 or Martin to Daniel G. Martin at Dan@MartinVentures.net; and (c) to IC or Irvin to Dwain Morris-Irvin at DIrvin@NovAccessGlobal.com.

 

9.2         Entire Agreement. This Agreement constitutes the entire agreement between the Parties and supersedes all other agreements, whether oral or written, with respect to the subject matter of this Agreement. This Agreement may be modified or amended only by a written agreement signed by the Parties against whom the amendment is sought to be enforced.

 

9.3         Governing Law. This Agreement will be governed by the laws of Ohio without giving effect to applicable conflict of law provisions. With respect to any litigation arising out of or relating to this Agreement, each party agrees that it will be filed in and heard by the state or federal courts with jurisdiction to hear such suits located in Cuyahoga County, Ohio.

 

9.4         Assignment. This Agreement may not be assignable by a Party without prior written consent of the other Parties.

 

9.5         Counterparts. This Agreement may be executed in any number of counterparts, including electronically, each of which counterparts will be deemed to be an original, and such counterparts will constitute but one and the same instrument.

 

< Signatures on Next Page >

 

 

8

 

 

In Witness Whereof, the Parties have signed this Agreement as of the date listed above.

 

	
			NovAccess Global Inc.

				 	
			TN3, LLC

			
	 	 	 
	
			/s/ Neil J. Laird

				 	
			/s/ Daniel G. Martin

			
	
			By Neil J. Laird

			Chief Financial Officer

				 	
			By Daniel G. Martin

			Sole Member and Manager

			
	 	 	 
	
			Irvin Consulting, LLC

				 	
			Daniel G. Martin

			
	 	 	 
	
			/s/ Dwain Morris-Irvin

				 	
			/s/ Daniel G. Martin

			
	
			By Dwain Morris-Irvin

			Sole Member and President

				 	
			Daniel G. Martin

			Individually

			
	 	 	 
	
			Dwain Morris-Irvin

				 	 
	 	 	 
	
			/s/ Dwain Morris-Irvin

				 	 
	
			Dwain Morris-Irvin

			Individually

				 	 

 

9

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00339-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00339-of-00352.parquet"}]]